Podcasts about Merck

  • 2,252PODCASTS
  • 4,770EPISODES
  • 33mAVG DURATION
  • 2DAILY NEW EPISODES
  • Jul 30, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about Merck

Show all podcasts related to merck

Latest podcast episodes about Merck

Pharma and BioTech Daily
Pharma and Biotech Daily: New Novo Nordisk CEO, FDA Reversal on Sarepta, and More

Pharma and BioTech Daily

Play Episode Listen Later Jul 30, 2025 0:49


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk has announced Maziar Mike Doustdar as its new CEO, along with a 5% reduction in its 2025 sales guidance. This decision comes as a response to the slowed growth of its semaglutide franchise in the U.S. Senate Democrats are currently looking into HHS Secretary RFK Jr.'s controversial move to dismiss all 17 members of the CDC's vaccine advisory committee. Astrazeneca CEO Pascal Soriot emphasized the importance of global collaboration in pharmaceutical research and development. Merck has allocated $3 billion to support upcoming product launches. In a surprising turn of events, the FDA has reversed its decision on Sarepta, now permitting DMD gene therapy for ambulatory patients.

BioSpace
Sarepta Gets Reprieve, RFK Jr.'s New Changes, Roche's Alzheimer's Comeback and Q2 Earnings

BioSpace

Play Episode Listen Later Jul 30, 2025 19:17


The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company's Duchenne muscular dystrophy gene therapy be lifted for ambulatory patients, after determining that the death of an 8-year-old Brazilian Duchenne patient who had received Elevidys' was not caused by the drug.  Sarepta's stock has swung wildly and its transparency questioned after it elected not to reveal the death of a third patient—a participant in a trial of a gene therapy for limb girdle muscular dystrophy—during a business update last week.    Speaking of entities—or individuals—who have trouble staying out of the news, Health Secretary Robert F. Kennedy Jr. plans to dissolve the U.S. Preventive Services Task Force because it is “too woke.” Also on Monday, Kennedy addressed what he called the “broken” vaccine injury compensation program. Without offering details, he vowed to “fix” the U.S.'s VICP and return it to its “original Congressional intent.”   On the business side of the biopharma house, Q2 earnings are in full swing, with AstraZeneca announcing estimate-beating numbers and CEO Pascal Soriot saying the world “needs to share” in global pharma R&D, while Merck cut $3 billion to support an aggressive launch schedule. Meanwhile, a week ahead of its own earnings report, Novo Nordisk named a new CEO and lowered its 2025 sales guidance for the second time this year.   In clinical development, the Alzheimer's Association Annual Conference is underway in Toronto, with Roche's trontinemab the standout so far. In a Phase Ib/IIa trial, the next-gen anti-amyloid antibody rapidly cleared amyloid from the brains of patients with Alzheimer's disease after just seven months—besting the 18-month timeframe for Biogen and Eisai's Leqembi and Eli Lilly's Kisunla. While Leqembi and Kisunla have shown some progress is slowing down the progression of Alzheimer's, their effect size is modest and they don't work for all patients—leaving plenty of room for symptomatic treatments, such as those being developed by Bristol Myers Squibb and Acadia Pharmaceuticals. The space is gearing up for several readouts, for both symptomatic and disease-modifying therapies alike.   And in BioPharm Executive this week, we dig into the top VC rounds so far this year and highlight a few scrappy biotechs walking the solo road.  

MONEY FM 89.3 - Your Money With Michelle Martin
Market View: From Scandals to Snack-Serving Robots — HPL, Envy, and the New Era of Trade

MONEY FM 89.3 - Your Money With Michelle Martin

Play Episode Listen Later Jul 30, 2025 25:01


What do F1-linked scandals, Ponzi schemes, and popcorn-serving robot dogs have in common? Hosted by Michelle Martin with Ryan Huang, today’s Market View dives into Hotel Properties Limited (HPL) and its Orchard Road asset play, and the fallout from Envy Asset Management’s billion-dollar nickel scam. We also unpack shifting US trade policy under President Trump and its implications for Singapore, with the 10% tariff still looming. In our corporate roundup, we dissect the latest from AstraZeneca, Merck, Novo Nordisk, UOB’s United Overseas Insurance, and First REIT. Finally, we marvel at Unitree, UBTech Robotics, and Agibot at China’s AI Summit. From legal woes to leaping robot dogs—don’t miss today’s episode.See omnystudio.com/listener for privacy information.

Unstoppable Mindset
Episode 357 – Unstoppable Manager and Leader with Scott Hanton

Unstoppable Mindset

Play Episode Listen Later Jul 29, 2025 66:45


“Manager and leader”? What's the difference. During my conversation this time with Scott Hanton, our guest, we will discuss this very point along with many other fascinating and interesting subjects. As Scott tells us at the beginning of this episode he grew up asking “why” about most anything you can think of. He always was a “why” asker. As he tells it, unlike many children who grow out of the phase of asking “why” he did not. He still asks “why” to this very day.   At the age of 13 Scott decided that he wanted to be a chemist. He tells us how this decision came about and why he has always stayed with it. Scott received his bachelor's degree in Chemistry from Michigan State and his PHD from the University of Wisconsin. Again, why he changed schools for his PHD work is an interesting story. As you will see, Scott tells stories in a unique and quite articulate way.   After his university days were over Scott went to work, yes as a chemist. He tells us about this and how after 20 years with one company how and why he moved to another company and somewhat out of constant lab work into some of the management, business and leadership side of a second company. He stayed there for ten years and was laid off during the pandemic. Scott then found employment as the editorial director of Lab Management Magazine where he got to bring his love of teaching to the forefront of his work.   My hour with Scott gives us all many insights into management, leadership and how to combine the two to create a strong teaming environment. I believe you will find Scott's thoughts extremely poignant and helpful in everything that you do.     About the Guest:   Scott Hanton is the Editorial Director of Lab Manager. He spent 30 years as a research chemist, lab manager, and business leader at Air Products and Intertek. Scott thrives on the challenges of problem-solving. He enjoys research, investigation, and collaboration. Scott is a people-centric, servant leader. He is motivated by developing environments where people can grow and succeed, and crafting roles for people that take advantage of their strengths.   Scott earned a BS in chemistry from Michigan State University and a PhD in physical chemistry from the University of Wisconsin-Madison. He is an active member of the American Chemical Society (ACS), the American Society of Mass Spectrometry (ASMS), and the Association of Lab Managers (ALMA). As a scientist Scott values curiosity, innovation, progress, and delivery of results. Scott has always been motivated by questions beginning with why. Studying physical chemistry in graduate school offered the opportunity to hone answers to these questions. As a professional scientist, Scott worked in analytical chemistry specializing in MALDI mass spectrometry and polymer characterization.   At Scott married his high school sweetheart, and they have one son. Scott is motivated by excellence, happiness, and kindness. He most enjoys helping people and solving problems. Away from work, Scott enjoys working outside in the yard, playing strategy games, and participating in different discussion groups.   Scott values having a growth mindset and is a life-long learner. He strives to learn something new everyday and from everyone. One of the great parts of being a trained research scientist is that failure really isn't part of his vocabulary. He experiments and either experiences success or learns something new. He values both individual and organizational learning.   Scott's current role at Lab Manager encompasses three major responsibilities: ·      Writing articles and giving presentations to share his experience with lab managers. ·      Driving the creation and growth of the Lab Manager Academy (https://labmanageracademy.com/) that currently contains three certificate programs: lab management, lab safety management, and lab quality management. ·      Helping people through his knowledge of science, scientists, management, and leadership. He is very happy sharing the accumulated wisdom of his experiences as a researcher, lab supervisor, and lab manager. Each article posted on Lab Manager addresses a decision that a lab manager needs to make. Lab management is full of decision-making, so helping people make better, faster, more complete decisions is very satisfying. Ways to connect with Scott:   https://www.linkedin.com/in/scott-hanton/   About the Host:   Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog.   Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards.   https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/   accessiBe Links https://accessibe.com/ https://www.youtube.com/c/accessiBe https://www.linkedin.com/company/accessibe/mycompany/ https://www.facebook.com/accessibe/       Thanks for listening!   Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below!   Subscribe to the podcast   If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can subscribe in your favorite podcast app. You can also support our podcast through our tip jar https://tips.pinecast.com/jar/unstoppable-mindset .   Leave us an Apple Podcasts review   Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts.       Transcription Notes:   Michael Hingson ** 00:00 Access Cast and accessiBe Initiative presents Unstoppable Mindset. The podcast where inclusion, diversity and the unexpected meet. Hi, I'm Michael Hingson, Chief Vision Officer for accessiBe and the author of the number one New York Times bestselling book, Thunder dog, the story of a blind man, his guide dog and the triumph of trust. Thanks for joining me on my podcast as we explore our own blinding fears of inclusion unacceptance and our resistance to change. We will discover the idea that no matter the situation, or the people we encounter, our own fears, and prejudices often are our strongest barriers to moving forward. The unstoppable mindset podcast is sponsored by accessiBe, that's a c c e s s i capital B e. Visit www.accessibe.com to learn how you can make your website accessible for persons with disabilities. And to help make the internet fully inclusive by the year 2025. Glad you dropped by we're happy to meet you and to have you here with us.   Michael Hingson ** 01:20 Well, welcome to another episode of unstoppable mindset where inclusion diversity and the unexpected meet, and mostly we get to deal with the unexpected, as opposed to inclusion or diversity. But that's okay, because unexpected is what makes life fun, and our guest today, Scott Hanton, will definitely be able to talk about that. Scott has been a research chemist. He comes from the chemistry world, so he and I in the past have compared notes, because, of course, I come from the physics world, and I love to tell people that the most important thing I learned about physics was that, unlike Doc Brown, although I do know how to build a bomb, unlike Doc Brown from Back to the Future, I'm not dumb enough to try to go steal fissionable material from a terrorist group to build the bomb. So, you know, I suppose that's a value, value lesson somewhere. But anyway, I am really glad that you're all here with us today, and we have lots to talk about. Scott, as I said, was in chemistry and research chemist, and now is the editorial supervisor and other things for a magazine called lab manager, and we will talk about that as well. So Scott, welcome to unstoppable mindset. We're glad   Scott Hanton ** 02:38 you're here. Thank you for having me. I'm excited to have this conversation with you today.   Michael Hingson ** 02:43 Well, I think it'll be a lot of fun, and looking forward to it. Now, you're in Michigan, right?   Scott Hanton ** 02:48 That's right. I live in South Lyon, Michigan,   Michael Hingson ** 02:51 ah, what's the weather back there today?   Scott Hanton ** 02:55 It's probably about 55 degrees and cloudy   Michael Hingson ** 02:58 here today. Well, it's still fairly sunny here, and we're actually, according to my iPhone, at 71 so it was up around 80 earlier in the week, but weather changes are still going to bring some cold for a while   Scott Hanton ** 03:15 in here in Michigan, I visited a customer earlier this week, and I drove by about 1000 orange barrels on the highway, which means it's spring, because there's only two seasons in Michigan, winter and construction.   Michael Hingson ** 03:29 There you go. Yeah, I know. I went to the University of California, Irvine, UCI. And if you ask somebody who doesn't know that UCI stands for University of California at Irvine. If you ask them what UCI stands for, they'll tell you, under construction indefinitely. Sounds right? Yeah. Well, it's been doing it ever since I was there a long time ago, and they they continue to grow. Now we're up to like 32,000 fresh, or excuse me, undergraduates at the university. And when I was there, there were 2700 students. So it's grown a little. That's   Scott Hanton ** 04:05 a lot of change. I'm used to big universities. I'm a graduate of both Michigan State and the University of Wisconsin. So these are big places.   Michael Hingson ** 04:13 Wow, yeah. So you're used to it. I really enjoyed it when it was a small campus. I'm glad I went there, and that was one of the reasons that caused me to go there, was because I knew I could probably get a little bit more visibility with instructors, and that would be helpful for me to get information when they didn't describe things well in class. And it generally worked out pretty well. So I can't complain a lot. Perfect. Glad it worked well for you, it did. Well, why don't you start, if you would, by telling us kind of about the early Scott growing up and all that sort of stuff.   Scott Hanton ** 04:49 I grew up in Michigan, in a town called Saginaw. I was blessed with a family that loved me and that, you know, I was raised in a very. Supportive environment. But young Scott asked, Why about everything you know, the way kids do? Yeah, right. And my mom would tell you that when I was a kid, why was my most favorite word? And most kids outgrow that. I never did, yeah, so Me neither. I still ask why all the time. It's still my most favorite word, and it caused me to want to go explore the sciences, because what I found, as I learned about science, was that I could get answers to why questions better in science than in other places.   Michael Hingson ** 05:34 Yeah, makes sense. So what kinds of questions did you ask about why? Well, I asked   Scott Hanton ** 05:43 all kinds of questions about why, like, why are we having that for dinner? Or, why is my bedtime so early? Those questions didn't have good answers, at least from my perspective, right? But I also asked questions like, why is grass green, and why is the sky blue? And studying physical chemistry at Michigan State answered those questions. And so   Michael Hingson ** 06:03 how early did you learn about Rayleigh scattering? But that's you know?   Scott Hanton ** 06:07 Well, I learned the basic concepts from a really important teacher in my life, Mr. Leeson was my seventh grade science teacher, and what I learned from him is that I could ask questions that weren't pertinent to what he was lecturing about, and that taught me a lot about the fact that science was a lot bigger than what we got in the curriculum or in the classroom. And so Mr. Leeson was a really important person in my development, and showed me that there was that science was a lot bigger than I thought it was as a student, but I didn't really learn about rally scattering until I got to college.   Michael Hingson ** 06:43 But at the same time, it sounds like he was willing to allow you to grow and and learn, which so many people aren't willing to do. They're too impatient.   Scott Hanton ** 06:58 He was a first year teacher the year I had him so he hadn't become cynical yet. So it was great to just be able to stay after class and ask him a question, or put my hand up in class and ask him a question. He also did a whole series of demonstrations that were fabulous and made the science come to life in a way that reading about it doesn't stir the imagination. Yeah,   Michael Hingson ** 07:23 I had teachers that did that too. I remember very well my freshman general science teacher in high school, Mr. Dills, and one day, and he loved to do kind of unique things, just to push the boundaries of students a little bit. He came in one day and he said, I got a pop quiz for everybody, which doesn't help me, because the pop quiz was in print, but he handed it out. And then he took me to the back of the room, and he said, You're not going to really be able to do this quiz. Let me tell you why. And he said, Oh, and one thing he said is, just be sure you follow all the instructions and you'll be fine on the test to everybody. He brought me back to the back of the room. He says, Well, here's the deal. He says, if people really read the instructions, what they'll do is they'll read the instruction that says, Read all the questions before you start answering, and if you get to the last question, it says answer only the first question, which is what is your name and and sure enough, of course, people didn't read the instructions. And he said, so I wouldn't be able to really deal with you with that one, with that whole thing, just because it wouldn't work well. And I said, I understand, but he loved to make students think, and I learned so much about the whole concept of realizing the need to observe and be observant in all that you do. And it was lessons like that from him that really helped a lot with that. For me,   Scott Hanton ** 08:48 I had a high school chemistry teacher named Mrs. Schultz, and the first experiment that we did in her class, in the first week of classes, was she wanted us to document all of the observations that we could make about a burning candle. And I was a hot shot student. Thought I, you know, owned the world, and I was going to ace this test. And, you know, I had maybe a dozen observations about a burning candle, and thought I had done a great job describing it, until she started sharing her list, and she probably had 80 observations about a burning candle, and it taught me the power of observation and the need to talk about the details of those observations and to be specific about what the observations were. And that experiment seems simple, light a candle and tell me what you see. Yeah, but that lesson has carried on with me now for more than approaching 50 years.   Michael Hingson ** 09:47 Let's see, as I recall, if you light a candle, what the center of the flame is actually pretty cool compared to the outside. It's more hollow. Now I wouldn't be able to easily tell that, because. Is my my process for observing doesn't really use eyesight to do that, so I I'm sure there are other technologies today that I could use to get more of that information. But   Scott Hanton ** 10:12 I'm also sure that that experiment could be re crafted so that it wasn't so visual, yeah, right, that there could be tactile experiments to tell me about observations or or audible experiments about observation, where you would excel in ways that I would suffer because I'm so visually dominant. The   Michael Hingson ** 10:33 issue, though, is that today, there's a lot more technology to do that than there was when I was in school and you were in school, but yeah, I think there is a lot available. There's a company called Independence Science, which is actually owned and run by Dr Cary sapollo. And Carrie is blind, and he is a blind chemist, and he wanted to help develop products for blind people to be able to deal with laboratory work. So he actually worked with a company that was, well, it's now Vernier education systems. They make a product called LabQuest with something like 80 different kinds of probes that you can attach to it, and the LabQuest will will provide visual interpretations of whatever the probes are showing carry, and independent science took that product and made it talk, so that There is now a Talking LabQuest. And the reality is that all those probes became usable because the LabQuest became accessible to be able to do that, and they put a lot of other things into it too. So it's more than just as a talking device, a lab device. It's got a periodic table in it. It's got a lot of other kinds of things that they just put in it as well. But it's really pretty cool because it now makes science a whole lot more accessible. I'm going to have to think about the different kinds of probes and how one could use that to look at a candle. I think that'd be kind of fun.   Scott Hanton ** 12:15 And it's just awesome to hear that there's innovation and space to make science more available to everybody. Yeah,   Michael Hingson ** 12:23 the real problem that we face is the one that we mostly always have faced, which is societal attitudes, as opposed to really being or not being able to do the experiments, is people think we can't, and that's the barrier that we always, usually have to overcome.   Scott Hanton ** 12:39 What I find in my time as a coach, mentor, supervisor, is that if somebody believes they can't do it, they can't do it. Yeah. And so it's often about overcoming their own mental limitations, the limitations that they've placed on themselves,   Michael Hingson ** 12:56 and that's right, or unfortunately, the limitations that other people place on us, and we, all too often and weigh too much, buy into those limitations. So it's it is something that we, especially in the sciences, should recognize that we shouldn't be doing so much of. I know that when I was at UC Irvine as a graduate student, I learned once that there was a letter in my file that a professor wrote. Fortunately, I never had him as a professor, but it and I was in my master's program at the time in physics, and this guy put a letter in my file saying that no blind person could ever absorb the material to get an advanced degree in physics at the University. Just put that in there, which is so unfortunate, because the real thing that is demonstrated there is a prejudice that no scientist should ever have.   Scott Hanton ** 13:51 I'm hopeful that as you graduated, there was a retraction letter in your file as well,   Michael Hingson ** 13:57 not that I ever heard, but yeah. Well, I'd already gotten my bachelor's degree, but yeah. But you know, things happen, but it is a it is a societal thing, and society all too often creates limitations, and sometimes we don't find them right away, but it is one of the big issues that, in general, we have to deal with. And on all too often, society does some pretty strange things because it doesn't understand what science is all about. I know when we were dealing with covid, when it all started, leaving the conspiracy theorists out of it. One of the things that I learned was that we have all these discussions about AI, if you will. But AI was one of the primary mechanisms that helped to develop the mRNA vaccines that are now still the primary things that we use to get vaccinated against covid, because they the artificial intelligence. I'm not sure how artificial. It is, but was able to craft what became the vaccine in a few days. And scientists acknowledged, if they had to do it totally on their own, it would take years to have done what AI did in a few days.   Scott Hanton ** 15:13 The AI technology is amazing and powerful, but it's not new. No, I met a person who shared her story about AI investigations and talked about what she was doing in this field 30 years ago. Yeah, in her master's work. And you know, I knew it wasn't brand new, but I didn't really realize how deep its roots went until I talked to her.   Michael Hingson ** 15:37 I worked as my first jobs out of college with Ray Kurzweil, who, of course, nowadays, is well known for the singularity and so on. But back then, he developed the first reading machine that blind people could use to read printed material. And one of the things that he put into that machine was the ability, as it scanned more material, to learn and better recognize the material. And so he was doing machine learning back in the 1970s   Scott Hanton ** 16:07 right? And all of this is, you know, as Newton said on the shoulders of giants, right, right? He said it a bit cynically, but it's still true that we all in science, we are learning from each other. We're learning from the broader community, and we're integrating that knowledge as we tackle the challenges that we are exploring.   Michael Hingson ** 16:27 So what got you to go into chemistry when you went into college?   Scott Hanton ** 16:33 That's a good question. So when I was 13 years old, I went on a youth a church group youth trip to another city, and so they split us up, and there were three of us from our group that stayed overnight in a host family. And at dinner that night, the father worked in a pharmaceutical company, and he talked about the work he was doing, and what he was doing was really synthetic chemistry around small molecule drug discovery. And for me, it was absolutely fascinating. I was thrilled at that information. I didn't know any scientists growing up, I had no adult input other than teachers about science, and I can remember going back home and my parents asking me how the trip went. And it's like, it's fantastic. I'm going to be a chemist. And they both looked at me like, what is that? How do you make money from it? How do you get that? My dad was a banker. My mom was a school teacher. They had no scientific background, but that that one conversation, such serendipity, right? One conversation when I was 13 years old, and I came home and said, I'm going to be a chemist, and I've never really deviated from that path. Did you have other siblings? Younger brother and another younger sister?   Michael Hingson ** 17:54 Okay? Did they go into science by any remote chance?   Scott Hanton ** 17:58 Not at all. So they were both seventh grade teachers for more than 30 years. So my brother taught math and English, and my sister teaches social studies.   Michael Hingson ** 18:10 Well, there you go. But that is also important. I actually wanted to teach physics, but jobs and other things and circumstances took me in different directions, but I think the reality is that I ended up going into sales. And what I realized, and it was partly because of a Dale Carnegie sales course I took, but I realized that good sales people are really teachers, because they're really teaching people about products or about things, and they're also sharp enough to recognize what their products might or might not do to help a customer. But that, again, not everyone does that, but so I figure I still was teaching, and today, being a public speaker, traveling the world, talking, of course, about teamwork and other things, it's still all about teaching.   Scott Hanton ** 18:57 I think I've always been a teacher, and if you talk to my coworkers along the way, I enjoy helping people. I enjoy sharing my knowledge. There's always been a teacher inside but only in this job as the editorial director at lab manager have I really been able to do it directly. So we've developed what we call the lab manager Academy, and I create e learning courses to help lab managers be more successful, and it's been a passion project for me, and it's been a load of fun.   Michael Hingson ** 19:30 And it doesn't get better than that. It's always great when it's a load of fun, yes,   Scott Hanton ** 19:35 well, so you left college and you got a bachelor's and a master's degree, right? No masters for me, that step you went right to the old PhD, yeah. So I went straight. I went graduated from Michigan State. So Michigan State was on terms back in those days. So graduated in June, got married in July, moved to Wisconsin in August. To graduate school at the end of August at the University of Wisconsin. Okay? And my second year as a graduate student, my professor asked me, Do you want to stop and complete a master's? And I said, Wait, tell me about this word stop. And he said, Well, you'd have to finish the Master's requirements and write a thesis, and that's going to take some time. And I said, Do I have to and he said, No, and I don't recommend it. Just keep going forward and finish your PhD. So that's   Michael Hingson ** 20:30 and what does your wife do?   Scott Hanton ** 20:33 So my wife also is in the graduate program at the University of Wisconsin, and she decided that a master's degree was the right answer for her, because she didn't want to be a PhD scientist in XYZ narrow band of science. She wanted to be a master of chemistry. Okay, and so we took different paths through graduate school, but each of us took the path that worked best for us, and each pass has great value, so we're both happy with the choices that we made,   Michael Hingson ** 21:06 and complement each other and also give you, still lots of great things to talk about over dinner.   Scott Hanton ** 21:12 Absolutely. And she took that master's degree, went into the pharmaceutical industry and largely behaved as a librarian in her first part of her career, she wasn't called a librarian, but what she really did was a lot of information integrating, and then moved into the Library Group, and was a corporate librarian for a long time, and then a community librarian. So that path worked brilliantly for her. She also has a Masters of Library Science. So I have one PhD. She has two Master's degree. I have one bachelor's degree. She has two bachelor's degree.   Michael Hingson ** 21:50 Oh, so you can have interesting discussions about who really progressed further,   21:54 absolutely.   Michael Hingson ** 21:57 Well, that's, that's, that's cute, though. Well, I I got my bachelor's and master's. My wife, who I didn't meet until years later, wanted to be a librarian, but she ended up getting a a Master's at USC in so in sociology and and ended up getting a teaching credential and going into teaching, and taught for 10 years, and then she decided she wanted to do something different, and became a travel agent, which she had a lot of fun with. That is different, it is, but she enjoyed it, and along the way, then we got married. It was a great marriage. She was in a wheelchair her whole life. So she read, I pushed, worked out well, complimentary skills, absolutely, which is the way, way it ought to be, you know, and we had a lot of fun with it. Unfortunately, she passed now two and a half years ago, but as I tell people, we were married 40 years, and I'm sure she's monitoring me from somewhere, and if I misbehave, I'm going to hear about it, so I try to just behave. Sounds like good advice. Yeah, probably certainly the safe way to go. But we, we, we had lots of neat discussions, and our our activities and our expertise did, in a lot of ways, complement each other, so it was a lot of fun. And as I said, she went to USC. I enjoyed listening to USC football because I thought that that particular college team had the best announcers in the business, least when when I was studying in Southern California, and then when we got married, we learned the the day we got married, the wedding was supposed to start at four, and it didn't start till later because people weren't showing up for the wedding. And we learned that everybody was sitting out in their cars waiting for the end of the USC Notre Dame game. And we knew that God was on our side when we learned that SC beat the snot out of Notre Dame. So there you go. Yeah. Yeah. Oh gosh, the rivalries we face. So what did you do after college?   Scott Hanton ** 24:09 So did my PhD at the University of Wisconsin. And one of the nice things, a fringe benefit of going to a big, important program to do your PhD, is that recruiters come to you. And so I was able to do 40 different, four, zero, 40 different interviews on campus without leaving Madison. And one of those interviews was with a company called Air Products. And that worked out, and they hired me. And so we moved to Allentown, Pennsylvania to go to work. I went to work at Air Products and and Helen found a role in the pharmaceutical industry at Merck. And so we did that for a long time. I was initially a research expert, a PhD expert doing lasers and materials and analytical stuff. And over the years. I progressed up the ladder from researcher to supervisor to what did we call it, group head to Section Manager, to operations manager, and ultimately to General Manager.   Michael Hingson ** 25:13 Well, at least being in Allentown, you were close to a Cracker Barrel restaurant. Yes, that is true. That was the closest to one to where we lived in New Jersey, so we visited it several times. That's how I know   Scott Hanton ** 25:26 about it. Maybe we were there at the same time. Michael, maybe this isn't our first. It's   Michael Hingson ** 25:31 very possible. But we enjoyed Cracker Barrel and enjoyed touring around Pennsylvania. So I should have asked, What prompted you to go to the University of Wisconsin to do your your graduate work, as opposed to staying in Michigan. So   Scott Hanton ** 25:47 my advisor at Michigan State, our advisor at Michigan State, told us, here's the top five schools, graduate programs in chemistry, apply to them all. Go to the one you get into. And so I got into three. Helen got into two. The one that was the same was Wisconsin. So that's where we went, yeah?   Michael Hingson ** 26:09 Well, then no better logic and argument than that.   Scott Hanton ** 26:14 It was a great Madison. Wisconsin is a beautiful city. It one of the things I really liked about the chemistry program there then, and it's still true now, is how well the faculty get along together so many collaborative projects and just friendliness throughout the hallways. And yes, they are all competing at some level for grant support, but they get along so well, and that makes it for a very strong community,   Michael Hingson ** 26:41 and it probably also means that oftentimes someone who's applying for something can enlist support from other people who are willing to help.   Scott Hanton ** 26:50 And as a graduate student, it meant that I had more than one professor that I could go to my advisor. There was a whole group of advisors who ran joint group meetings and would give us advice about our work or our writing or our approach, or just because we needed a pep talk, because completing a PhD is hard. Yeah, right, so that community was really important to me, and it's something I took away that when I started my industrial career, I had seen the value of community, and I wanted to build stronger communities wherever I went, yeah.   Michael Hingson ** 27:26 So what does a company, does air products do   Scott Hanton ** 27:31 that's sort of in the name, right? They're an industrial gas company. Got some of their big, biggest products are taking air and separating it into its components of nitrogen, oxygen, oxygen, argon, whatever, right? But at that time, they also had a chemicals business and a semiconductor business, or electronics business. So there was a lot of chemistry going on, although a lot of my work colleagues were chemical engineers who were working on the gasses side of the business, we had significant number of chemistry, sorts material science, sorts of people who are working on the chemicals side. Now, over time, Air Products divested those businesses, and now it's much more of a true industrial gas company. But I had the opportunity to work in an integrated science company that did all sorts of things.   Michael Hingson ** 28:23 Yeah, and as as we know, certainly a little helium never hurt anyone.   Scott Hanton ** 28:30 No little helium, you know, raises people's spirits, it   Michael Hingson ** 28:34 does and their voices, it does. I I've visited helium tanks many times at UC Irvine when they had liquid helium, which was certainly a challenge because of how cold it had to be. But occasionally we would open a valve and little cold but useful helium gas would escape   Scott Hanton ** 28:56 very cold. Please be safe. Cryogens are are dangerous materials, and we gotta make sure we handle them with due respect.   Michael Hingson ** 29:05 Yeah, well, we, we all did and and didn't take too many chances. So it worked out pretty well. So you stayed in Allentown and you stayed with Air Products for how long   Scott Hanton ** 29:19 I was in Air Products for 20 years. So the analytical group that I was part of, we were about 92 or 93 people when I joined the company, when I just left after earning my PhD. After 20 years, that group was down to about 35 just progressive series of decisions that made the department smaller, and as the Department got smaller and smaller, we were worried about our abilities to sustain our work. And so a dear friend and a key colleague, Paula McDaniel, and I, worked to try to see what other kind of opportunities there were. Yeah. And so we reached out to a contract research organization called Intertech to see if they would be interested in maybe acquiring our analytical department. And when we called them, and by the way, we called them before we talked to our boss about it, she forgave us later, but when we called the guy on the end of the phone said, Wait a minute, let me get your file. And it's like, what you have a file on Air Products, analytical, really? Why? Well, it turned out that they had a file, and that they had an active Merger and Acquisition Group, and they wanted an integrated analytical department on the east coast of the US. And so we engaged in negotiation, and ultimately this analytical department was sold by Air Products to Intertech. So on Friday, we're a little cog in a giant engine of an global, international company, and our funding comes from Vice Presidents. And on Monday, we're a standalone business of 35 people, we need to write quotes in order to make money. So it was an enormous challenge to transition from a service organization to a business. But oh my goodness, did we learn a lot,   Michael Hingson ** 31:13 certainly a major paradigm shift,   Scott Hanton ** 31:18 and I was lucky that I lost the coin flip, and Paula won, and she said, I want to be business development director. And I said, thank God. So she went off to be the key salesperson, and Paula was utterly brilliant as a technical salesperson, and I became the operations manager, which allowed me to keep my hands dirty with the science and to work with the scientists and to build a system and a community that allowed us to be successful in a CRO world.   Michael Hingson ** 31:49 So at that time, when you became part, part of them, the new company, were you or the standalone business? Were you working in lab? Still yourself?   Scott Hanton ** 32:01 Yes. So I had the title Operations Manager and all of the scientific staff reported into me, but I was still the technical expert in some mass spectrometry techniques, particularly MALDI and also tough Sims, and so I still had hands on lab responsibility that I needed to deliver. And over time, I was able to train some people to take some of those responsibilities off. But when the weight of the world was particularly heavy, the place for me to go was in the lab and do some experiments.   Michael Hingson ** 32:34 Yeah, still so important to be able to keep your hand in into to know and understand. I know I had that same sort of need being the manager of an office and oftentimes working with other people who were the engineers, coming from a little bit of a technical background as well. I worked to always make sure I knew all I could about the products that I was dealing with and selling, and my sales people who worked for me constantly asked, How come, you know, all this stuff, and we don't then, my response always was, did you read the product bulletin that came out last week? Or have you kept up on the product bulletins? Because it's all right there, whether I actually physically repaired products or not, I knew how to do it. And so many times when I was involved in working with some of our engineers, I remember a few times our field support people, and we were working out of New Jersey, and then in New York at the time, in the World Trade Center, we had some customers up at Lockheed Martin, up in Syria, Rochester, I think it was. And the guys would go up, and then they'd call me on the phone, and we'd talk about it, and between us, we came up with some bright ideas. And I remember one day, all of a sudden, I get this phone call, and these guys are just bouncing off the walls, because whatever it was that was going on between them and me, we figured it out, and they put it in play and made it work, and they were all just as happy as clams at high tide, which is the way it ought to   Scott Hanton ** 34:13 be. It's great to work in a team that finds success. The longer I was in technical management, the more I enjoyed the success of the team. It didn't need to be my success anymore that helping the scientists be successful in their roles was truly satisfying,   Michael Hingson ** 34:33 and that helped you, by definition, be more successful in your role.   Scott Hanton ** 34:36 And no question, it could be seen as a selfish byproduct, but the fact is that it still felt really good.   Michael Hingson ** 34:43 Yeah, I hear you, because I know for me, I never thought about it as I've got to be successful. It's we've got problems to solve. Let's do it together. And I always told people that we're a team. And I have told every salesperson. I ever hired. I'm not here to boss you around. You've convinced me that you should be able to sell our products, and sometimes I found that they couldn't. But I said my job is to work with you to figure out how I can enhance what you do, and what skills do I bring to add value to you, because we've got to work together, and the people who understood that and who got it were always the most successful people that I ever had in my teams.   Scott Hanton ** 35:30 One of the things I strive to do as a leader of any organization is to understand the key strengths of the people on the team and to try to craft their roles in such a way that they spend the majority of their time executing their strengths. Yeah. I've also discovered that when I truly investigate poor performance, there's often a correlation between poor performance and people working in their weaknesses. Yeah, and if we can shift those jobs, change those roles, make change happen so that people can work more often in their strengths, then good things happen.   Michael Hingson ** 36:07 And if you can bring some of your skills into the mix and augment what they do, so much the better.   Scott Hanton ** 36:16 Yeah, because I'm just another member of the team, my role is different, but I need to also apply my strengths to the problems and be wary of my weaknesses, because as the leader of the organization, my words carried undue weight. Yeah, and if, if I was speaking or acting in a space where I was weak, people would still do what I said, because I had the most authority, and that was just a lose, lose proposition   Michael Hingson ** 36:43 by any standard. And and when you, when you operated to everyone's strengths, it always was a win. Yep, which is so cool. So you went to Intertech, and how long were you there?   Scott Hanton ** 36:57 I was at Intertech for 10 years, and work I can if you know, for any listeners out there who work in the CRO world, it is a tough business. It is a grind working in that business, yeah? So it was a lot of long hours and testy customers and shortages of materials and equipment that was a hard a hard a hard road to plow,   Michael Hingson ** 37:22 yeah, yeah, it gets to be frustrating. Sometimes it's what you got to do, but it still gets to be frustrating gets to be a challenge. The best part   Scott Hanton ** 37:32 for me was I had a great team. We had senior and junior scientists. They were good people. They worked hard. They fundamentally, they cared about the outcomes. And so it was a great group of people to work with. But the contract lab business is a tough business. Yeah, so when covid came, you know, the pandemic settles in, all the restrictions are coming upon us. I was tasked as the General Manager of the business with setting up all the protocols, you know, how are we going to meet the number of people this basing the masks, you know, how could we work with and we were essential as a lab, so we had to keep doing what we were doing. And it took me about a week to figure non stop work to figure out what our protocols were going to be, and the moment I turned them into my boss, then I got laid off. So what you want to do in a time of crisis is you want to let go of the the general manager, the safety manager, the quality manager and the Chief Scientist, because those are four people that you don't need during times of stress or challenge or crisis. On the plus side for me, getting laid off was a bad hour. It hurt my pride, but after an hour, I realized that all the things that I'd been stressing about for years trying to run this business were no longer my problem. Yeah, and I found that it was a tremendous weight lifted off my shoulders to not feel responsible for every problem and challenge that that business had.   Michael Hingson ** 39:14 And that's always a good blessing when you when you figure that out and don't worry about the the issues anymore. That's a good thing. It was certainly   Scott Hanton ** 39:25 good for me. Yeah, so I'm not going to recommend that people go get laid off. No world to get fired. But one problem that I had is because Paula and I worked to create that business, I sort of behaved like an owner, but was treated like an employee. And my recommendation to people is, remember, you're an employee, find some personal boundaries that protect you from the stress of the business, because you're not going to be rewarded or treated like an owner.   Michael Hingson ** 39:58 Yeah, because you're not because. Or not.   Scott Hanton ** 40:01 So I got laid off. It was in the height of the pandemic. So, you know, I'm too busy of a human being to sort of sit in a rocking chair and watch the birds fly by. That's not my style or my speed. So I started a consulting business, and that was a lot of fun. I really enjoyed doing the consulting work, but I learned something really important about myself, and that's that while I can sell and I can be an effective salesperson, I don't like selling, and as a company of one, when I didn't sell, I didn't make any money, yeah, and so I needed to figure out something else to do, because I really hated selling, and I wasn't doing it. I was procrastinating, and that made the business be unpredictable and very choppy   Michael Hingson ** 40:51 in that company of one, that guy who was working for you wasn't really doing all that you wanted.   Scott Hanton ** 40:56 Exactly the Yeah, you know me as the founder, was giving me as the salesman, a poor performance review was not meeting objectives. So I had a long time volunteer relationship with lab manager magazine. I had been writing articles for them and speaking for them in webinars and in conferences for a long time, probably more than 10 years, I would say, and they asked me as a consultant to produce a a to a proposal to create the lab manager Academy. So the the founder and owner of the the company, the lab X Media Group, you really saw the value of an academy, and they needed it done. They needed it done. They couldn't figure it out themselves. So I wrote the proposal. I had a good idea of how to do it, but I was new to consulting, and I struggled with, how do I get paid for this? And I had four ideas, but I didn't like them, so I slept on it, and in the morning I had a fifth, which said, hire me full time. I sent in the proposal. An hour later, I had a phone call. A week later, I had a job, so that worked out fantastic. And I've really enjoyed my time at lab manager magazine. Great people, fun work. It's really interesting to me to be valued for what I know rather than for what I can do. Yeah,   Michael Hingson ** 42:23 the two relate. But still, it does need to be more about what you know, what you really bring, as opposed to what you can do, because what you can do in general probably is an offshoot of what you know.   Scott Hanton ** 42:38 So this gives me the opportunity to help lots of people. So on the outside of the company, I'm writing articles, creating courses, giving talks to help lab managers. Because I was a lab manager for a long time, yeah, over 20 years, and I know what those challenges are. I know how hard that job is, and I know how many decisions lab managers need to make, and it's wonderful to be able to share my experience and help them, and I am motivated to help them. So was it hard? Oh, go ahead, on the inside, I'm literally an internal subject matter expert, and so I can coach and teach and help my colleagues with what's the science? What do lab managers really think? How do we pitch this so that it resonates with lab managers, and I think that helps make all of our products better and more successful.   Michael Hingson ** 43:31 So was it hard? Well, I guess best way to put it is that, was it really hard to switch from being a scientist to being a lab manager and then going into being a subject matter expert and really out of the laboratory. So   Scott Hanton ** 43:48 people ask me all the time, Scott, don't you miss being in the lab and doing experiments? And my answer is, I miss being in the lab. And I do miss being in the lab. You know, on very stressful days at Intertech, I'd go in the lab and I'd do an experiment, yeah, because it was fun, and I had more control over the how the experiment was run and what I would learn from it than I did running a business. But the flip side of that is, I do experiments all the time. What I learned as the general manager of a business was the scientific method works. Let's data hypothesis. Let's figure out how to test it. Let's gather data, and let's see if the hypothesis stands or falls. And we ran a business that way, I think, pretty successfully. And even now, in in media and publishing, we still run experiments all the time. And it's kind of funny that most of my editorial colleagues that I work with, they think my favorite word is experiment. My favorite word is still why, but we talk all the time now about doing experiments, and that was a new thing for them, but now we can do continual improvement more in a more dedicated way, and we do it a lot faster. Yeah,   Michael Hingson ** 45:00 yeah. So what's the hardest thing you think about being a lab manager?   Scott Hanton ** 45:06 I think the hardest thing about let me answer that with two. I'm not going to be able to narrow it down to one, so I'll give you two. The first one is you transform, maybe one day to the next, from really being in control of your science and working with whether it's animals or rocks or electrons or chemicals, whatever you're working with, having a great degree of knowledge and a lot of control, and the next day, you're hurting cats. And so it's about that transition from having control over your destiny to influencing people to get the work done, and working with people instead of working with experiments, that's really hard. The second is, as a lab manager, there's endless decisions, and so combating decision fatigue is a big deal, and everybody in the lab depends upon you for the decisions you make. And it's not that every decision has to be perfect, you know, that's just a different failure mode if you try to make perfect decisions, but every decision needs to be made promptly. And as a scientist, I could always make more data in order to make a better decision, but as a lab manager, I would often only have maybe 40 or 50% of the data I wanted, and a decision had to be made. And getting comfortable making decisions in the face of uncertainty is really hard.   Michael Hingson ** 46:29 So certainly, being a lab manager or Well, dealing with managers in the way we're talking about it here, has to be very stressful. How do you how do you cope with the stress?   Scott Hanton ** 46:42 So I think ways to cope with the stress successfully is, first of all, you've got to take care of yourself. You know, we've all flown on airplanes, and what is the safety person in the aisle or on the video? Do oxygen masks will fall from the ceiling, and what do we do with them? We put them on before we help somebody else, right? We all know that. But in the workplace, especially as a manager, it's hard to remember that as we care for our team and try and take care of our team, there might not be enough time or energy or capacity left to take care of ourselves, but if we don't fill that gas tank every day doing something, then we can't help our team. And so one way to deal with the stress is to make sure that you take care of yourself. So   Michael Hingson ** 47:28 what do you do? How do you deal with that? So   Scott Hanton ** 47:31 for me, ways that I can reinvigorate is one. I like being outside and get my hands dirty. So I'm not really a gardener, but I call myself a yard dinner. So I grow grass and I grow flowers, and I trim trees, and I want to go outside, and I want to see immediate return on my effort, and I want it to be better than when I started. And it's good if I have to clean from under my fingernails when I'm doing it. Another thing I like to do is I play all kinds of games I'm happy to play, sorry, with little kids, or I'll play complicated strategy games with people who want to sit at a table for three or four hours at a time. Yeah? And that allows my brain to spin and to work but on something completely different. Yeah. And another thing that's been important for me, especially when I was a lab manager is to be involved in youth coaching, so I coached kids soccer and basketball and baseball teams, and it's just beautiful to be out there on a field with a ball, with kids. And you know, the worries of the world just aren't there. The kids don't know anything about them. And it's fun to work with the ones who are really good, but it's equally fun to work with the ones who have never seen the ball before, and to help them do even the most basic things. And that kind of giving back and paying it forward, that sort of stuff fills my tank.   Michael Hingson ** 48:51 Yeah, I empathize a lot with with that. For me, I like to read. I've never been much of a gardener, but I also collect, as I mentioned before, old radio shows, and I do that because I'm fascinated by the history and all the things I learned from what people did in the 2030s, 40s and 50s, being on radio, much Less getting the opportunity to learn about the technical aspects of how they did it, because today it's so different in terms of how one edits, how one processes and deals with sounds and so on, but it's but it's fun to do something just totally different than way maybe what your normal Job would be, and and I do love to interact with with people. I love to play games, too. I don't get to do nearly as much of it as I'd like, but playing games is, is a lot of fun,   Scott Hanton ** 49:52 and I agree, and it it's fun, it's diverting, it's it helps me get into a flow so that I'm focused on. Me on one thing, and I have no idea how much time has gone by, and I don't really care. You know, people who play games with me might question this. I don't really care if I win or lose. Certainly I want to win, but it's more important to me that I play well, and if somebody plays better, good for   Michael Hingson ** 50:14 them, great. You'll learn from it. Exactly. Do you play   Scott Hanton ** 50:18 chess? I have played chess. I've played a lot of chess. What I've learned with chess is that I'm not an excellent I'm a good player, but not an excellent player. And when I run into excellent players, they will beat me without even breaking a sweat.   Michael Hingson ** 50:34 And again, in theory, you learn something from that.   Scott Hanton ** 50:37 What I found is that I don't really want to work that hard and yeah. And so by adding an element of chance or probability to the game, the people who focus on chess, where there are known answers and known situations, they get thrown off by the uncertainty of the of the flip the card or roll the dice. And my brain loves that uncertainty, so I tend to thrive. Maybe it's from my time in the lab with elements of uncertainty, where the chess players wilt under elements of uncertainty, and it's again, it's back to our strengths, right? That's something that I'm good at, so I'm gonna go do it. I've   Michael Hingson ** 51:20 always loved Trivial Pursuit. That's always been a fun game that I enjoy playing. I   Scott Hanton ** 51:25 do love Trivial Pursuit. I watch Jeopardy regularly. A funny story, when we moved into our new house in Pennsylvania, it was a great neighborhood. Loved the neighbors there. When we first moved in, they invited my wife and I to a game night. Excellent. We love games. We're going to play Trivial Pursuit. Awesome like Trivial Pursuit. We're going to play as couples. Bad idea, right? Let's play boys against the girls, or, let's say, random draws. No, we're playing as couples. Okay, so we played as couples. Helen and I won every game by a large margin. We were never invited back for game night. Yeah, invited back for lots of other things, but not game night.   Michael Hingson ** 52:06 One of the things that, and I've talked about it with people on this podcast before, is that all too often, when somebody reads a question from a trivial pursuit card, an answer pops in your head, then you went, Oh, that was too easy. That can't be the right answer. So you think about it, and you answer with something else, but invariably, that first answer was always the correct answer.   Scott Hanton ** 52:32 Yes, I'm I have learned to trust my intuition. Yeah. I learned, as a research scientist, that especially in talking to some of my peers, who are very dogmatic, very step by step scientists. And they lay out the 20 steps to that they felt would be successful. And they would do one at a time, one through 20. And that made them happy for me, I do one and two, and then I'd predict where that data led me, and I do experiment number seven, and if it worked, I'm off to eight. And so I they would do what, one step at a time, one to 20, and I'd sort of do 127, 1420, yeah. And that I learned that that intuition was powerful and valuable, and I've learned to trust it. And in my lab career, it served me really well. But also as a manager, it has served me well to trust my intuition, and at least to listen to it. And if I need to analyze it, I can do that, but I'm going to listen to it,   Michael Hingson ** 53:31 and that's the important thing, because invariably, it's going to give you useful information, and it may be telling you not what to do, but still trusting it and listening to it is so important, I've found that a lot over the years,   Scott Hanton ** 53:47 Malcolm Gladwell wrote a book called Blink, where he talks about the power of the subconscious, and his claim is that the subconscious is 100,000 times smarter than our conscious brain, and I think when we are trusting our intuition, we're tapping into that super computer that's in our skulls. If you want to learn more, read blank. It's a great story.   Michael Hingson ** 54:10 I hear you. I agree. How can people learn to be better leaders and managers?   Scott Hanton ** 54:18 So I think it's there's really three normal ways that people do this. One is the power of experiment, right? And I did plenty of that, and I made tons of errors. It's painful. It's irritating, trial and error, but I used to tell people at Intertech that I was the general manager because I'd made the most mistakes, which gave me the most opportunity to learn. It was also partly because a lot of my peers wanted nothing to do with the job. You know, they wanted to be scientists. Another way is we, we get coached and mentored by people around us, and that is awesome if you have good supervisors, and it's tragic if you have bad supervisors, because you don't know any better and you take for granted. That the way it's been done is the way it needs to be done, and that prevents us from being generative leaders and questioning the status quo. So there's problems there, too. And I had both good and bad supervisors during my career. I had some awful, toxic human beings who were my supervisors, who did damage to me, and then I had some brilliant, caring, empathetic people who raised me up and helped me become the leader that I am today. So it's a bit of a crap shoot. The third way is go out and learn it from somebody who's done it right, and that's why we generated the lab manager Academy to try to codify all the mistakes I made and what are the learnings from them? And when I'm talking with learners who are in the program, it's we have a huge positive result feedback on our courses. And what I talk to people about who take our courses is I'm glad you appreciate what we've put together here. That makes me feel good. I'm glad it's helping you. But when these are my mistakes and the answers to my mistakes, when you make mistakes, you need to in the future, go make some courses and teach people what the lessons were from your mistakes and pay it forward. Yeah. So I recommend getting some training.   Michael Hingson ** 56:17 What's the difference between management and leadership?   Scott Hanton ** 56:21 I particularly love a quote from Peter Drucker. So Peter Drucker was a professor in California. You may have heard of him before.   Michael Hingson ** 56:29 I have. I never had the opportunity to meet him, but I read.   Scott Hanton ** 56:34 I didn't either material. I've read his books, and I think he is an insightful human being, yes. So the quote goes like this, management is doing things right. Leadership is doing the right things. So as a technical manager, there's a bunch of things we have to get right. We have to get safety right. We have to get quality right. There's an accuracy and precision that we need to get right for our outcomes and our results. Those are management tasks, but leadership is about doing the right things. And the interesting thing about that definition is it doesn't require a title or a role or any level of authority. So anyone can be a leader if you're consistently doing the right things, you are exhibiting leadership, and that could be from the person sweeping the floors or the person approving the budget, or anyone in between.   Michael Hingson ** 57:33 Yeah, I've heard that quote from him before, and absolutely agree with it. It makes a whole lot of sense.   Scott Hanton ** 57:41 Other definitions that I've seen trying to distinguish management and leadership tend to use the words manage and lead, and I don't like definitions that include the words that they're trying to define. They become circular at some level. This one, I think, is clear about it, what its intention is, and for me, it has worked through my career, and so the separation is valuable. I have authority. I'm the manager. I have accountability to get some stuff right, but anyone can lead, and everyone can lead, and the organization works so much better when it's full of leaders   Michael Hingson ** 58:21 and leaders who are willing to recognize when they bring something to the table, or if someone else can add value in ways that they can't, to be willing to let the other individual take the leadership position for a while.   Scott Hanton ** 58:40 Absolutely, and you know that really comes down to building an environment and a culture that's supportive. And so Amy Edmondson has written extensively on the importance of psychological safety, and that psychological safety hinges on what you just said, right? If the guy who sweeps the floor has an observation about the organization. Do they feel safe to go tell the person in charge that this observation, and if they feel safe, and if that leader is sufficiently vulnerable and humble to listen with curiosity about that observation, then everybody benefits, yeah, and the more safe everyone feels. We think about emotion. Emotional safety is they anyone can bring their best self to work, and psychological safety is they can contribute their ideas and observations with no threat of retaliation, then we have an environment where we're going to get the best out of everybody, yeah,   Michael Hingson ** 59:46 which is the way it it really ought to be. And all too often we don't necessarily see it, but that is the way it ought   Scott Hanton ** 59:53 to be. Too many people are worried about credit, or, I don't know, worried about things that I don't see. Yeah, and they waste human potential, right? They they don't open their doors to hire anybody. They they judge people based on what they look like instead of who they are, or they box people in into roles, and don't let them flourish and Excel. And whenever you're doing those kinds of things, you're wasting human potential. And businesses, science and business are too hard to waste human potential. We need to take advantage of everything that people are willing to give. Yeah,   Michael Hingson ** 1:00:33 we've been doing this for quite a while already today. So I'm going to ask as a kind of a last question, what, what advice do you want to leave for people to think about going forward in their lives and in their careers?   Scott Hanton ** 1:00:48 So I was participating in a LinkedIn chat today where a professor was asking the question, what sort of advice would you wish you got when you were 21 Okay, so it was an interesting thread, and there was one contributor to the thread who said something I thought was particularly valuable. And she said, attitude matters. Attitude matters. We can't control what happens to us, but we can control how we deal with it and how we respond, right? And so I think if we can hold our attitude as our accountability, and we can direct our strengths and our talents to applying them against the challenges that the business or the science or the lab or the community faces, and we can go in with some positive attitude and positive desire for for change and improvement, and we can be vulnerable and humble enough to accept other people's ideas and to interact through discussion and healthy debate. Then everything's better. I also like Kelleher his quote he was the co founder of Southwest Airlines, and he said, when you're hiring, hire for attitude, train for skill. Attitude is so important. So I think, understand your attitude. Bring the attitude you want, the attitude you value, the attitude that's that's parallel to your core values. And then communicate to others about their attitude and how it's working or not working for them.   Michael Hingson ** 1:02:31 And hopefully, if they have a positive or good enough attitude, they will take that into consideration and grow because of it absolutely   Scott Hanton ** 1:02:41 gives everybody the chance to be the best they can be.   Michael Hingson ** 1:02:47 Well, Scott, this has been wonderful. If people want to reach out to you, how can they do that?   Scott Hanton ** 1:02:51 So LinkedIn is great. I've provided Michael my LinkedIn connection. So I would love to have people connect to me on LinkedIn or email. S Hanson at lab manager.com love to have interactions with the folks out there.   Michael Hingson ** 1:03:08 Well, I want to thank you for spending so much time. We'll have to do more of this.   Scott Hanton ** 1:03:13 Michael, I really enjoyed it. This was a fun conversation. It was stimulating. You asked good questio

Ransquawk Rundown, Daily Podcast
Europe Market Open: Lacklustre trade as the week's risk events kick off

Ransquawk Rundown, Daily Podcast

Play Episode Listen Later Jul 29, 2025 4:24


APAC stocks traded with a mostly negative bias after a similar performance among global peers.European equity futures indicate a positive cash market open with Euro Stoxx 50 future up 0.2% after the cash market closed with gains of 0.3%.FX markets are contained, EUR/USD sits on a 1.15 handle, USD/JPY maintains its footing above the 148 mark.Bund futures lacked direction overnight. Crude futures were little changed but held on to most of the prior day's spoils.Looking ahead, highlights include Spanish GDP Estimate, US Advance Goods Trade Balance, Wholesale Inventories Advance, Consumer Confidence, Dallas Fed Services Revenues, Atlanta Fed GDPNow, ECB SCE, Supply from UK, Germany & US.Earnings from AstraZeneca, Barclays, Unite, L'Oreal, Air Liquide, Orange, Kering, Banca Generali, Terna, Endesa, Grifols, Visa, Marathon Digital, Starbucks, Booking, UnitedHealth, Sofi, Paypal, UPS, Spotify, Merck, Nucor, JetBlue, Procter & Gamble.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Ransquawk Rundown, Daily Podcast
US Market Open: Stocks firmer & USD continues to gain ahead of JOLTS, consumer confidence and earnings

Ransquawk Rundown, Daily Podcast

Play Episode Listen Later Jul 29, 2025 3:30


European bourses are broadly in the green, alongside strength in US futures ahead of a busy earnings slate.USD is firmer, EUR/USD's descent continues as markets digest the EU-US trade agreement.USTs await data and a 7yr auction, Bunds are on the backfoot giving back some of the prior day's upside.Crude resumes upside while metals are hampered by the Dollar.Looking ahead, highlights include US JOLTS Job Openings, Advance Goods Trade Balance, Wholesale Inventories Advance, Consumer Confidence, Dallas Fed Services Revenues, Atlanta Fed GDPNow, ECB SCE, Supply from the US, Earnings from Kering, Banca Generali, Terna, Grifols, Visa, Marathon Digital, Starbucks, Booking, UnitedHealth, Sofi, Paypal, UPS, Spotify, Merck, Nucor, JetBlue, Procter & Gamble.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

NY to ZH Täglich: Börse & Wirtschaft aktuell
Überwiegend flaue Ergebnisse | New York to Zürich Täglich

NY to ZH Täglich: Börse & Wirtschaft aktuell

Play Episode Listen Later Jul 29, 2025 16:50


Die Wall Street tendiert zwar freundlich, mit überwiegend aber negativen Reaktionen auf Quartalzahlen. Die Aktien von Merck, Novo Nordisk, UnitedHealth, UPS, Whirlpool, Stanley Black &Decker, Royal Caribbean, Spotify und PayPal notieren nach den Zahlen alle teils deutlich schwächer. Aufwärts geht es nach den Ergebnissen lediglich bei Boeing, Procter & Gamble und Corning. Nach dem Closing melden Starbucks, Mondelez und Booking Holdings. Heute enden die Gespräche zwischen den USA und China in Stockholm. Die Wall Street geht davon aus, dass die Pause der zeitweise deutlich angehobenen Zölle von Washington um 90 Tage verlängert wird. Die Wall Street rechnet erst im Herbst mit einer Einigung. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

Wall Street mit Markus Koch
Teils deutlich negative Reaktionen auf Ergebnisse

Wall Street mit Markus Koch

Play Episode Listen Later Jul 29, 2025 21:10


Die Wall Street tendiert zwar freundlich, mit überwiegend aber negativen Reaktionen auf Quartalzahlen. Die Aktien von Merck, Novo Nordisk, UnitedHealth, UPS, Whirlpool, Stanley Black &Decker, Royal Caribbean, Spotify und PayPal notieren nach den Zahlen alle teils deutlich schwächer. Aufwärts geht es nach den Ergebnissen lediglich bei Boeing, Procter & Gamble und Corning. Nach dem Closing melden Starbucks, Mondelez und Booking Holdings. Heute enden die Gespräche zwischen den USA und China in Stockholm. Die Wall Street geht davon aus, dass die Pause der zeitweise deutlich angehobenen Zölle von Washington um 90 Tage verlängert wird. Die Wall Street rechnet erst im Herbst mit einer Einigung. Ein Podcast - featured by Handelsblatt. +++Erhalte einen exklusiven 15% Rabatt auf Saily eSIM Datentarife! Lade die Saily-App herunter und benutze den Code wallstreet beim Bezahlen: https://saily.com/wallstreet +++ +++EXKLUSIVER NordVPN Deal ➼ https://nordvpn.com/Wallstreet Jetzt risikofrei testen mit einer 30-Tage-Geld-zurück-Garantie!+++ +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html

Börsenradio to go Marktbericht
Börsenradio Schlussbericht, Di., 29.07.25 - Der DAX holt sich die 24.000 zurück...

Börsenradio to go Marktbericht

Play Episode Listen Later Jul 29, 2025 22:29


Der DAX holt sich die Marke von 24.000 Punkten zurück – plus 1,0 % auf 24.200. Das EU-USA-Zollabkommen sorgt für Klarheit, die Börsen feiern. Boeing und MTU überzeugen, UPS und Süss Microtec enttäuschen. Der Euro fällt nach dem Deal weiter, Gold legt zu. Heiko Thieme analysiert die geopolitischen Folgen, ein neuer Wikifolio-Trader spricht über seine Strategie. Jetzt reinhören und informiert bleiben!

Progress, Potential, and Possibilities
Bill Taranto - President, Merck Global Health Innovation Fund - Scaling Impactful Innovation

Progress, Potential, and Possibilities

Play Episode Listen Later Jul 28, 2025 45:13


Send us a textBill Taranto is President of the Merck Global Health Innovation Fund ( MGHIF - https://www.msdghifund.com/ ).The Merck Global Health Innovation Fund was established in late 2010 as a strategic response to the challenges surrounding Merck's core business of discovering, developing and marketing innovative drugs and vaccines.Bill has more than three decades of experience in the healthcare industry. MGHIF is a $750m evergreen fund focused on identifying opportunities that are adjacent to Merck's core business of pharmaceuticals and vaccines. Under Bill's leadership, MGHIF has invested more than $1bn in 70 companies, with more than $7bn in exits.Prior to joining Merck, Bill spent 18 years at Johnson & Johnson (J&J) in various roles. As VP of healthcare strategy and venture at J&J, he was responsible for evaluating and creating new healthcare business models through venture capital and acquisitions. Prior to joining J&J, Bill spent eight years in investment banking.#BillTaranto #MerckGlobalHealthInnovationFund #Scale #Impact #InvestmentBanking #DrugDiscovery #ClinicalDevelopment #Manufacturing #SupplyChain #RealWorldEvidence #CorporateVentureCapital #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcastSupport the show

Alles auf Aktien
Teslas vage Visionen und Alphabets erstaunlicher KI-Spagat

Alles auf Aktien

Play Episode Listen Later Jul 24, 2025 23:29


In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über die IBM-Schwäche T-Mobile's Mega-Cash-Flow und Hoffnung auf einen finalen Zoll-Deal zwischen Amerika und der EU. Außerdem geht es um SAP, Siemens Energy, GE Vernova, Microsoft, Service Now, Abivax, Porsche, Volkswagen, BMW, Mercedes-Benz, Merck, Bayer, BASF, Brenntag, DHL, Boeing, Siemens, Amazon, Gea Group, Knorr Bremse, Evonik, Puma, Campari, Remy Cointreau. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Morgans Financial Limited
Morning Meeting - Thursday, July 24 2025

Morgans Financial Limited

Play Episode Listen Later Jul 23, 2025 7:19


US equity markets advanced amid some positive news and headlines in the trade front, while investors continued to wade through the latest quarterly earnings releases - Dow rallied +508-points or +1.14% to 45.010.29, falling just shy of recording its first record closing high since December. All of Boeing Co (up +2.36%), Caterpillar Inc (+2.49%), Chevron Corp (+2.05%), Goldman Sachs Group Inc (+2.44%), Merck & Co Inc (+2.90%), UnitedHealth Group Inc (+2.59%) and Nvidia Corp (+2.25%) rising over >2%.

Gude, Rheinhessen!
Ärger über Versammlungen an der Christuskirche

Gude, Rheinhessen!

Play Episode Listen Later Jul 23, 2025 6:05


Beschwerden über regelmäßige Versammlungen an der Mainzer Christuskirche, der Mainzer Haushalt für 2025 und ein Erfolg gegen Tumorerkrankungen bei Merck. Das und mehr heute im Podcast. Alle Hintergründe zu den Nachrichten des Tages finden Sie hier: https://www.allgemeine-zeitung.de/lokales/mainz/stadt-mainz/kaiserstrasse-mainzer-beklagen-laerm-chaos-und-drogenhandel-4775795 https://www.allgemeine-zeitung.de/lokales/mainz/stadt-mainz/wo-in-mainz-jetzt-gespart-gestrichen-oder-erhoeht-wird-4749108 https://www.allgemeine-zeitung.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/springworks-coup-bringt-merck-bahnbrechendes-tumormedikament-4812136 https://www.allgemeine-zeitung.de/lokales/mainz/stadt-mainz/leonardo-hotel-mainz-vor-offizieller-eroeffnung-in-betrieb-4812748 https://www.allgemeine-zeitung.de/politik/politik-rheinland-pfalz/immer-weniger-fluechtlinge-kommen-nach-rheinland-pfalz-4815084 Ein Angebot der VRM.

Gude, Südhessen!
Magnum investiert Millionen in Langnese-Werk in Heppenheim

Gude, Südhessen!

Play Episode Listen Later Jul 23, 2025 6:21


Gute Nachrichten für das Langnese-Werk in Heppenheim, Darmstadts Drogenhilfeeinrichtung Sentral zieht um und ein Erfolg gegen Tumorerkrankungen bei Merck. Das und mehr heute im Podcast. Alle Hintergründe zu den Nachrichten des Tages finden Sie hier: https://www.echo-online.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/springworks-coup-bringt-merck-bahnbrechendes-tumormedikament-4812136 https://www.echo-online.de/lokales/kreis-darmstadt-dieburg/rossdorf/fuenf-verletzte-bei-wohnungsbrand-in-gundershauen-4814830 https://www.echo-online.de/lokales/kreis-bergstrasse/heppenheim-bergstrasse/das-hat-die-magnum-ice-cream-company-in-heppenheim-vor-4778586 https://www.echo-online.de/lokales/darmstadt/darmstadts-drogenhilfeeinrichtung-scentral-ist-bezugsfertig-4794921 https://www.echo-online.de/lokales/kreis-darmstadt-dieburg/griesheim/griesheimer-uebergeben-petition-gegen-grundsteuererhoehung-4797575 Ein Angebot der VRM.

Gude, Wiesbaden!
Umgestaltung der Nerostraße in Wiesbaden läuft

Gude, Wiesbaden!

Play Episode Listen Later Jul 23, 2025 6:16


Bauarbeiten an Wiesbadener Straßen beginnen, weniger Wolfsaktivität in Hessen und ein Erfolg in der Tumorbekämpfung bei Merck. Das und mehr heute im Podcast. Alle Hintergründe zu den Nachrichten des Tages finden Sie hier: https://www.wiesbadener-kurier.de/lokales/wiesbaden/stadt-wiesbaden/baustelle-mainzer-strasse-warum-von-oben-wenig-zu-sehen-ist-4803351 https://www.wiesbadener-kurier.de/lokales/wiesbaden/stadt-wiesbaden/umgestaltung-der-nerostrasse-in-wiesbaden-beginnt-4807705 https://www.wiesbadener-kurier.de/sport/fussball/fussball-dritte-liga/tobias-keller-hat-mit-dem-svww-ambitionierte-ziele-4816714 https://www.wiesbadener-kurier.de/lokales/rhein-main/aktuell-gibt-es-weniger-sesshafte-woelfe-in-hessen-4804875 https://www.wiesbadener-kurier.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/springworks-coup-bringt-merck-bahnbrechendes-tumormedikament-4812136 Ein Angebot der VRM.

Biotech Clubhouse
Episode 147 - July 11, 2025

Biotech Clubhouse

Play Episode Listen Later Jul 22, 2025 59:08


On this week's episode, Eric Schmidt, Brad Loncar, Tim Opler and Tess Cameron kick off with a discussion on the surgein biotech M&A, with 2025 almost matching 2024's deal count and surpassing it in value ($40B YTD vs $30B), highlighting recent deals like Merck's acquisition of Verona and AbbVie's purchase of Capstan. The group debateswhether this signals a true “M&A wave,” noting pharma's $150 billion of LOE approaching and reduced macro uncertainty could be driving deal flow. They alsonote a current competitive dynamic around commercial-stage assets. Shifting to policy, Trump's “Big Beautiful Bill” introduces key IRA exemptions for rare diseases and on tariffs, the co-hosts note the market's quiet reaction andwonder if investors are becoming desensitized to D.C. headlines. As M&A steadies and drug launches hold strong despite pricing pressure, some stability seems to be on the way. On the regulatory front, the group praises the FDA'simproved communication under new leadership, citing their strong online presence and experience with media. Despite the FDA's recent rejection of Capricor's cell therapy for DMD, optimism remains about the therapy's potential. Despite the improved communication discussed earlier, questionsabout the FDA's transparency arise following the agency's issuance of CRLs to be more transparent; it remains uncertain if this trend will continue. Conversation shifts to data, overviewing KalVista's approval of Ekterly, thefirst oral calcineurin inhibitor approved for hereditary angioedema attacks and ProKidney's cell therapy that showed improved eGFR slope in CKD patients in aPhase 2 trial, skyrocketing shares. The episode closes with a conversation on obesity trends. *This episode aired on July 11, 2025. 

Morgans Financial Limited
Morgans AM - Wednesday, 23 July 2025

Morgans Financial Limited

Play Episode Listen Later Jul 22, 2025 5:48


US equity markets mixed as investors waded through the latest round of corporate earnings releases and eyed results from the first of the ‘Magnificent Seven' cohort of mega-capitalisation stocks after the closing bell of tonight's AEST session - Dow rose +179-points or +0.40%. Amgen Inc (up +3.32%) and Merck & Co Inc (+2.90%) were the leading performers in the 30-stock index. Nvidia Corp (down -2.54%) was the weakest Dow component overnight.

Dr. Joseph Mercola - Take Control of Your Health
FDA Approves RSV Shot Despite High Infant Risk - AI Podcast

Dr. Joseph Mercola - Take Control of Your Health

Play Episode Listen Later Jul 17, 2025 8:48


Story at-a-glance Merck's respiratory syncytial virus (RSV) shot clesrovimab (Enflonsia) was approved even though 11.71% of babies in the trial experienced serious adverse events, including seizures, brain injury, and death Infants who got clesrovimab had a 350% higher risk of upper respiratory infections — exactly the type of illness this shot claims to prevent The injection is given in a single, fixed dose regardless of infant weight, putting smaller, younger babies at greater risk due to disproportionately high exposure Babies who received the shot had a threefold increase in severe neurological reactions compared to those given a placebo Only about 25 babies in the U.S. succumb to RSV each year, making the known risks of clesrovimab far outweigh the threat the virus poses to most children

Sales Leadership Podcast
Episode 321: Justin Abrams, CEO @Aryo: TECH Should Lead You to PEOPLE. Modernizing Your Leadership Approach with AI.

Sales Leadership Podcast

Play Episode Listen Later Jul 16, 2025 59:57


Justin Abrams is the founder and CEO of the Aryo Consulting Group. For the past 12 years Justin and his team have helped hundreds of organizations around the world…from some of the most iconic global companies like Sony and Merck to some of the newest, fastest growing companies…create inflection points that fuel remarkable growth. Justin specializes in helping companies stimulate flat or falling sales, and move away from tired old playbooks that “used to work.” Every sales leader has a responsibility to have modern approaches for modern sales challenges. And today, Justin joins us and shares how some of the most successful teams in the world do exactly that. This is a timely message as leaders make 2nd half adjustments for the 2025 year. You can connect with Justin on LinkedIn here. (https://www.linkedin.com/in/justin-abrams-aryo-consulting/) You can check out Aryo here (https://aryocg.com/). For video excerpts of this and other episodes of the Sales Leadership Podcast, check out Sales Leadership United Here. (https://www.patreon.com/c/SalesLeadershipUnited)

Dear Cancer, I'm Beautiful
"The Critical Role of Genetic Counseling in Breast Cancer Prevention" with Dena Goldberg, Board Certified Genetic Counselor

Dear Cancer, I'm Beautiful

Play Episode Listen Later Jul 16, 2025 61:37


In this episode of Decoding Destiny: Navigating Breast Cancer with Genetic Insight, I'm joined by Dena Goldberg, board-certified genetic counselor and founder of Malibu Genetics. We talk about the critical role genetic counselors play in assessing breast cancer risk, and how genetic testing can guide treatment and preventive care. Dena also shares how she supports patients through the emotional impact of receiving test results—and how understanding your genetic risk can be both empowering and life-saving. We also look ahead at the future of genetic testing, including the promise of population screening and the ongoing push for more equitable access. Listen now to learn how genetic counseling can help you and your loved ones make informed, proactive decisions about breast cancer risk.  Special thanks to AstraZeneca and Merck for making this episode possible.

The Bird Bath
VetValue Connect, Merck Approval, Hill's new Pres, OH eVCPR

The Bird Bath

Play Episode Listen Later Jul 15, 2025 14:26


Third week of July, what'd you miss in vet med?VetValue Connect LaunchArchway Pets' AcquisitionAnnual Bravecto ApprovalHill's new PresidentOhio approves eVCPRHelpful links:The Bird Bath substackVetValue Connect Pre-RegistrationVVCA - Virtual Veterinary Care In The USA: Interactive Telemedicine Map

Breakfast Leadership
Simplify to Scale – Real Talk on Small Business Growth with Justin Abrams from Aryo Consulting

Breakfast Leadership

Play Episode Listen Later Jul 14, 2025 30:15


In this episode, Michael D. Levitt sits down with Justin, founder of Aryo Consulting Group, to unpack small businesses' real-world challenges in today's fast-paced economy. With a track record of helping over 350 companies—ranging from scrappy startups to established enterprises—Justin brings practical insight into what works (and what doesn't) when scaling a business.

The Zero100 Podcast: Digitally Reinventing Supply Chain
Novo Nordisk & Eli Lilly: Manufacturing Lessons from the GLP-1 Giants

The Zero100 Podcast: Digitally Reinventing Supply Chain

Play Episode Listen Later Jul 14, 2025 25:36


As GLP-1 drugs like Ozempic and Zepbound took the world by storm, Novo Nordisk and Eli Lilly faced a massive question: how do you fill the need at maximum speed? This week, we pull back the curtain on the strategies that allowed both companies to scale their manufacturing and cement market dominance, offering takeaways for any leader navigating unprecedented demand. Featuring: Principal Analysts Caroline Chumakov and Jenna Fink.Contextualizing the appetite for GLP-1s (0:46)Build, buy, acquire: How Novo Nordisk and Eli Lilly are meeting demand (04:05)The implications of Novo Nordisk's $16.5 billion Catalent acquisition (05:53)How to decide whether to acquire or outsource (07:23)Where in the world is GLP-1 manufacturing going next? (10:36)DTC, telehealth, and the future of GLP-1 channel strategy (13:16)How AI is driving pharma innovation at Novo Nordisk, Eli Lilly, Johnson & Johnson, and Merck (17:13)

Pharma Intelligence Podcasts
Scrip's Five Must-Know Things - July 14, 2025

Pharma Intelligence Podcasts

Play Episode Listen Later Jul 14, 2025 14:41


Audio roundup of selected biopharma industry content from Scrip over the business week ended July 11, 2025. In this episode: Merck & Co's Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee's Phase II eczema win; and a look at India's wave of licensing. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-TJX4YBGD5JDSHGRUTLYHWO2JMU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

ASCO eLearning Weekly Podcasts
Oncology and Suffering: Strategies on Coping with Grief for Health Care Professionals

ASCO eLearning Weekly Podcasts

Play Episode Listen Later Jul 14, 2025 33:26


Drs. Hope Rugo, Sheri Brenner, and Mikolaj Slawkowski-Rode discuss the struggle that health care professionals experience when terminally ill patients are suffering and approaches to help clinicians understand and respond to suffering in a more patient-centered and therapeutic way. TRANSCRIPT Dr. Hope Rugo: Hello, and welcome to By the Book, a monthly podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book.  I'm your host, Dr. Hope Rugo. I'm director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center, and I'm also the editor-in-chief of the Educational Book. On today's episode, we'll be exploring the complexities of grief and oncology and the struggle we experience as healthcare professionals when terminally ill patients are suffering. Our guests will discuss approaches to help clinicians understand and respond to suffering in a more patient-centered and therapeutic way, as outlined in their recently published article titled, “Oncology and Suffering: Strategies on Coping With Grief for Healthcare Professionals.” I'm delighted today to welcome Dr. Keri Brenner, a clinical associate professor of medicine, palliative care attending, and psychiatrist at Stanford University, and Dr. Mikołaj Sławkowski-Rode, a senior research fellow in philosophy in the Humanities Research Institute at the University of Buckingham, where he also serves as director of graduate research in p hilosophy. He is also a research fellow in philosophy at Blackfriars Hall at the University of Oxford and associate professor at the University of Warsaw.  Our full disclosures are available in the transcript of this episode. Dr. Brenner and Dr. Sławkowski-Rode, thanks for being on the podcast today. Dr. Keri Brenner: Great to be here, Dr. Rugo. Thank you so much for that kind introduction. Dr. Mikołaj Sławkowski-Rode: Thank you very much, Dr. Rugo. It's a pleasure and an honor. Dr. Hope Rugo: So I'm going to start with some questions for both of you. I'll start with Dr. Brenner. You've spoken and written about the concept of suffering when there is no cure. For oncologists, what does it mean to attune to suffering, not just disease? And how might this impact the way they show up in difficult conversations with patients? Dr. Keri Brenner: Suffering is something that's so omnipresent in the work of clinical oncology, and I like to begin by just thinking about what is suffering, because it's a word that we use so commonly, and yet, it's important to know what we're talking about. I think about the definition of Eric Cassell, who was a beloved mentor of mine for decades, and he defined suffering as the state of severe distress that's associated with events that threaten the intactness of a person. And my colleague here at Stanford, Tyler Tate, has been working on a definition of suffering that encompasses the experience of a gap between how things are versus how things ought to be. Both of these definitions really touch upon suffering in a person-centered way that's relational about one's identity, meaning, autonomy, and connectedness with others. So these definitions alone remind us that suffering calls for a person-centered response, not the patient as a pathology, but the panoramic view of who the patient is as a person and their lived reality of illness. And in this light, the therapeutic alliance becomes one of our most active ingredients in care. The therapeutic alliance is that collaborative, trusting bond as persons that we have between clinician and patient, and it's actually one of the most powerful predictors of meaningful outcomes in our care, especially in oncologic care.  You know, I'll never forget my first day of internship at Massachusetts General Hospital. A faculty lecturer shared this really sage insight with us that left this indelible mark. She shared, “As physicians and healers, your very self is the primary instrument of healing. Our being is the median of the medicine.” So, our very selves as embodied, relationally grounded people, that's the median of the medicine and the first most enduring medicine that we offer. That has really borne fruit in the evidence that we see around the therapeutic alliance. And we see this in oncologic care, that in advanced cancer, a strong alliance with one's oncologist truly improves a patient's quality of life, treatment adherence, emotional well-being, and even surpasses structured interventions like psychotherapeutic interventions. Dr. Hope Rugo: That's just incredibly helpful information and actually terminology as well, and I think the concept of suffering differs so much. Suffering comes in many shapes and forms, and I think you really have highlighted that. But many oncologists struggle with knowing what to do when patients are suffering but can't be fixed, and I think a lot of times that has to do with oncologists when patients have pain or shortness of breath or issues like that. There are obviously many ways people suffer. But I think what's really challenging is how clinicians understand suffering and what the best approaches to respond to suffering are in the best patient-centered and therapeutic way. Dr. Keri Brenner: I get that question a lot from my trainees in palliative care, not knowing what to do. And my first response is, this is about how to be, not about knowing what to do, but how to be. In our medical training, we're trained often how to think and treat, but rarely how to be, how to accompany others. And I often have this image that I tell my trainees of, instead of this hierarchical approach of a fix-it mentality of all we're going to do, when it comes to elements of unavoidable loss, mortality, unavoidable sufferings, I imagine something more like accompaniment, a patient walking through some dark caverns, and I am accompanying them, trying to walk beside them, shining a light as a guide throughout that darkness. So it's a spirit of being and walking with. And it's so tempting in medicine to either avoid the suffering altogether or potentially overidentify with it, where the suffering just becomes so all-consuming like it's our own. And we're taught to instead strike a balance of authentic accompaniment through it. I often teach this key concept in my palli-psych work with my team about formulation. Formulation is a working hypothesis. It's taking a step back and asking, “Why? Why is this patient behaving in this manner? What might the patient's core inner struggle be?” Because asking that “why” and understanding the nuanced dimensions of a patient's core inner struggle will really help guide our therapeutic interactions and guide the way that we accompany them and where we choose to shine that light as we're walking with them. And oftentimes people think, “Well Keri, that sounds so sappy or oversentimental,” and it's not. You know, I'm just thinking about a case that I had a couple months ago, and it was a 28-year-old man with gastric cancer, metastatic disease, and that 28-year-old man, he was actually a college Division I athlete, and his dad was an acclaimed Division I coach. And our typical open-ended palliative care questions, that approach, infuriated them. They needed to know that I was showing up confident, competent, and that I was ready, on my A-game, with a real plan for them to follow through. And so my formulation about them was they needed somebody to show up with that confidence and competence, like the Division I athletes that they were, to really meet them and accompany them where they were on how they were going to walk through that experience of illness. Dr. Hope Rugo: These kinds of insights are so helpful to think about how we manage something that we face every day in oncology care. And I think that there are many ways to manage this.  Maybe I'll ask Dr. Sławkowski-Rode one question just that I think sequences nicely with what you're talking about.  A lot of our patients are trying to think about sort of the bigger picture and how that might help clinicians understand and support patients. So, the whole concept of spirituality, you know, how can we really use that as oncology clinicians to better understand and support patients with advanced illness, and how can that help patients themselves? And we'll talk about that in two different ways, but we'll just start with this broader question. Dr. Mikołaj Sławkowski-Rode: I think spirituality, and here, I usually refer to spirituality in terms of religious belief. Most people in the world are religious believers, and it is very intuitive and natural that religious beliefs would be a resource that people who help patients with a terminal diagnosis and healthcare professionals who work with those patients appeal to when they try to help them deal with the trauma and the stress of these situations.  Now, I think that the interesting thing there is that very often the benefit of appealing to a religious belief is misunderstood in terms of what it delivers. And there are many, many studies on how religious belief can be used to support therapy and to support patients in getting through the experience of suffering and defeating cancer or facing a terminal diagnosis. There's a wealth of literature on this. But most of the literature focuses on this idea that by appealing to religious belief, we help patients and healthcare practitioners who are working with them get over the fact and that there's a terminal diagnosis determining the course of someone's life and get on with our lives and engaging with whatever other pursuits we might have, with our job if we're healthcare practitioners, and with the other things that we might be passionate about in our lives. And the idea here is that this is what religion allows us to do because we sort of defer the need to worry about what's going to happen to us until the afterlife or some perspective beyond the horizon of our life here.  However, my view is – I have worked beyond philosophy also with theologians from many traditions, and my view here is that religion is something that does allow us to get on with our life but not because we're able to move on or move past the concerns that are being threatened by illness or death, but by forming stronger bonds with these things that we value in our life in a way and to have a sense of hope that these will be things that we will be able to keep an attachment to despite the threat to our life. So, in a sense, I think very many approaches in the field have the benefit of religion upside down, as it were, when it comes to helping patients and healthcare professionals who are engaged with their illness and treating it. Dr. Hope Rugo: You know, it's really interesting the points that you make, and I think really important, but, you know, sometimes the oncologists are really struggling with their own emotional reactions, how they are reacting to patients, and dealing with sort of taking on the burden, which, Dr. Brenner, you were mentioning earlier. How can oncologists be aware of their own emotional reactions? You know, they're struggling with this patient who they're very attached to who's dying or whatever the situation is, but you want to avoid burnout as an oncologist but also understand the patient's inner world and support them. Dr. Keri Brenner: I believe that these affective, emotional states, they're contagious. As we accompany patients through these tragic losses, it's very normal and expected that we ourselves will experience that full range of the human experience as we accompany the patients. And so the more that we can recognize that this is a normative dimension of our work, to have a nonjudgmental stance about the whole panoramic set of emotions that we'll experience as we accompany patients with curiosity and openness about that, the more sustainable the work will become. And I often think about the concept of countertransference given to us by Sigmund Freud over 100 years ago. Countertransference is the clinician's response to the patient, the thoughts, feelings, associations that come up within us, shaped by our own history, our own life events, those unconscious processes that come to the foreground as we are accompanying patients with illness. And that is a natural part of the human experience. Historically, countertransference was viewed as something negative, and now it's actually seen as a key that can unlock and enlighten the formulation about what might be going on within the patient themselves even. You know, I was with a patient a couple weeks ago, and I found myself feeling pretty helpless and hopeless in the encounter as I was trying to care for them. And I recognized that countertransference within myself that I was feeling demoralized. It was a prompt for me to take a step back, get on the balcony, and be curious about that because I normally don't feel helpless and hopeless caring for my patients. Well, ultimately, I discovered through processing it with my interdisciplinary team that the patient likely had demoralization as a clinical syndrome, and so it's natural many of us were feeling helpless and hopeless also accompanying them with their care. And it allowed us to have a greater interdisciplinary approach and a more therapeutic response and deeper empathy for the patient's plight. And we can really be curious about our countertransferences. You know, a few months ago, I was feeling bored and distracted in a family meeting, which is quite atypical for me when I'm sharing serious illness news. And it was actually a key that allowed me to recognize that the patient was trying to distract all of us talking about inconsequential facts and details rather than the gravitas of her illness.  Being curious about these affective states really allows us to have greater sustainability within our own practice because it normalizes that human spectrum of emotions and also allows us to reduce unconscious bias and have greater inclusivity with our practice because what Freud also said is that what we can't recognize and say within our own selves, if we don't have that self-reflective capacity, it will come out in what we do. So really recognizing and having the self-awareness and naming some of these emotions with trusted colleagues or even within our own selves allows us to ensure that it doesn't come out in aberrant behaviors like avoiding the patient, staving off that patient till the end of the day, or overtreating, offering more chemotherapy or not having the goals of care, doing everything possible when we know that that might result in medically ineffective care. Dr. Hope Rugo: Yeah, I love the comments that you made, sort of weaving in Freud, but also, I think the importance of talking to colleagues and to sharing some of these issues because I do think that oncologists suffer from the fact that no one else in your life wants to hear about dying people. They don't really want to hear about the tragic cases either. So, I think that using your community, your oncology community and greater community within medicine, is an important part of being able to sort of process. Dr. Keri Brenner: Yes, and Dr. Rugo, this came up in our ASCO [Education] Session. I'd love to double click into some of those ways that we can do this that aren't too time consuming in our everyday practice. You know, within palliative care, we have interdisciplinary rounds where we process complex cases. Some of us do case supervision with a trusted mentor or colleague where we bring complex cases to them. My team and I offer process rounds virtually where we go through countertransference, formulation, and therapeutic responses on some tough cases.  You know, on a personal note, just last week when I left a family meeting feeling really depleted and stuck, I called one of my trusted colleagues and just for 3 minutes constructively, sort of cathartically vented what was coming up within me after that family meeting, which allowed me to have more of an enlightened stance on what to do next and how to be therapeutically helpful for the case. One of my colleagues calls this "friend-tors." They coined the phrase, and they actually wrote a paper about it. Who within your peer group of trusted colleagues can you utilize and phone in real time or have process opportunities with to get a pulse check on where what's coming up within us as we're doing this work? Dr. Hope Rugo: Yeah, and it's an interesting question about how one does that and, you know, maintaining that as you move institutions or change places or become more senior, it's really important.  One of the, I think, the challenges sometimes is that we come from different places from our patients, and that can be an issue, I think when our patients are very religious and the provider is not, or the reverse, patients who don't have religious beliefs and you're trying to sort of focus on the spirituality, but it doesn't really ring true. So, Dr. Sławkowski-Rode, what resources can patients and practitioners draw on when they're facing death and loss in the absence of, or just different religious beliefs that don't fit into the standard model? Dr. Mikołaj Sławkowski-Rode: You're absolutely right that this can be an extremely problematic situation to be in when there is that disconnect of religious belief or more generally spiritual engagement with the situation that we're in. But I just wanted to tie into what Dr. Brenner was saying just before. I couldn't agree more, and I think that a lot of healthcare practitioners, oncologists in particular who I've had the pleasure to talk to at ASCO and at other events as well, are very often quite skeptical about emotional engagement in their profession. They feel as though this is something to be managed, as it were, and something that gets in the way. And they can often be very critical of methods that help them understand the emotions and extend them towards patients because they feel that this will be an obstacle to doing their job and potentially an obstacle also to helping patients to their full ability if they focus on their own emotions or the burden that emotionally, spiritually, and in other ways the illness is for the patient. They feel that they should be focusing on the cancer rather than on the patient's emotions. And I think that a useful comparison, although, you know, perhaps slightly drastic, is that of combat experience of soldiers. They also need to be up and running and can't be too emotionally invested in the situation that they're in. But there's a crucial difference, which is that soldiers are usually engaged in very short bursts of activity with the time to go back and rethink, and they often have a lot of support for this in between. Whereas doctors are in a profession where their exposure to the emotions of patients and their own emotions, the emotions of families of patients is constant. And I think that there's a great danger in thinking that this is something to be avoided and something to compartmentalize in order to avoid burnout. I think, in a way, burnout is more sure to happen if your emotions and your attachment to your patients goes ignored for too long. So that's just following up on Keri's absolutely excellent points. As far as the disconnect is concerned, that's, in fact, an area in which I'm particularly interested in. That's where my research comes in. I'm interested in the kinds of connections that we have with other people, especially in terms of maintaining bonds when there is no spiritual belief, no spiritual backdrop to support this connection. In most religious traditions, we have the framework of the religious belief that tells us that the person who we've lost or the values that have become undermined in our life are something that hasn't been destroyed permanently but something that we can still believe we have a deep connection to despite its absence from our life. And how do you rebuild that sense of the existence of the things that you have perceivably lost without the appeal to some sort of transcendent realm which is defined by a given religion? And that is a hard question. That's a question, I think, that can be answered partly by psychology but also partly by philosophy in terms of looking at who we are as human beings and our nature as people who are essentially, or as entities that are essentially connected to one another. That connection, I believe, is more direct than the mediation of religion might at first suggest. I think that we essentially share the world not only physically, it's not just the case that we're all here, but more importantly, the world that we live in is not just the physical world but the world of meanings and values that helps us orient ourselves in society and amongst one another as friends and foes. And it is that shared sense of the world that we can appeal to when we're thinking about retaining the value or retaining the connection with the people who we have lost or the people who are helping through, go through an experience of facing death. And just to finish, there's a very interesting question, I think, something that we possibly don't have time to explore, about the degree of connection that we have with other people. So, what I've just been saying is something that rings more true or is more intuitive when we think about the connections that we have to our closest ones. We share a similar outlook onto the world, and our preferences and our moods and our emotions and our values are shaped by life with the other person. And so, appealing to these values can give us a sense of a continued presence. But what in those relationships where the connection isn't that close? For example, given the topic of this podcast, the connection that a patient has with their doctor and vice versa. In what sense can we talk about a shared world of experience? Well, I think, obviously, we should admit degrees to the kind of relationship that can sustain our connection with another person. But at the same time, I don't think there's a clear cutoff point. And I think part of emotional engagement in medical practice is finding yourself somewhere on that spectrum rather than thinking you're completely off of it. That's what I would say. Dr. Hope Rugo: That's very helpful and I think a very helpful way of thinking about how to manage this challenging situation for all of us.  One of the things that really, I think, is a big question for all of us throughout our careers, is when to address the dying process and how to do that. Dr. Brenner, you know, I still struggle with this – what to do when patients refuse to discuss end-of-life but they're very close to end of life? They don't want to talk about it. It's very stressful for all of us, even where you're going to be, how you're going to manage this. They're just absolutely opposed to that discussion. How should we approach those kinds of discussions? How do we manage that? How do you address the code discussion, which is so important? You know, these patients are not able to stay at home at end-of-life in general, so you really do need to have a code discussion before you're admitting them. It actually ends up being kind of a challenge and a mess all around. You know, I would love your advice about how to manage those situations. Dr. Keri Brenner: I think that's one of the most piercing and relevant inquiries we have within our clinical work and challenges. I often think of denial not as an all-or-nothing concept but rather as parts of self. There's a part of everyone's being where the unconscious believes it's immortal and will live on forever, and yet we all know intellectually that we all have mortality and finitude and transience, and that time will end. We often think of this work as more iterative and gradual and exposure based. There's potency to words. Saying, “You are dying within days,” is a lot higher potency of a phrase to share than, “This is serious illness. This illness is incurable. Time might be shorter than we hoped.” And so the earlier and more upstream we begin to have these conversations, even in small, subtle ways, it starts to begin to expose the patient to the concept so they can go from the head to the heart, not only knowing their prognosis intellectually but also affectively, to integrate it into who they are as a person because all patients are trying to live well while also we're gradually exposing them to this awareness of mortality within their own lived experience of illness. And that, ideally, happens gradually over time. Now, there are moments where the medical frame is very limited, and we might have short days, and we have to uptitrate those words and really accompany them more radically through those high-affective moments. And that's when we have to take a lot of more nuanced approaches, but I would say the more earlier and upstream the better. And then the second piece to that question as well is coping with our own mortality. The more we can be comfortable with our own transience and finitude and limitations, the more we will be able to accompany others through that. And even within my own life, I've had to integrate losses in a way where before I go in to talk to one of my own palliative care patients, one mantra I often say to myself is, “I'm just a few steps behind you. I don't know if it's going to be 30 days or 30 years, but I'm just a few steps behind you on this finite, transient road of life that is the human experience.” And that creates a stance of accompaniment that patients really can experience as they're traversing these tragedies. Dr. Hope Rugo: That's great. And I think those are really important points and actually some pearls, which I think we can take into the clinic. I think being really concrete when really the expected life expectancy is a few days to a couple of weeks can be very, very helpful. And making sure the patients hear you, but also continuing to let them know that, as oncologists, we're here for them. We're not abandoning them. I think that's a big worry for many, certainly of my patients, is that somehow when they would go to hospice or be a ‘no code', that we're not going to support them anymore or treat them anymore. That is a really important process of that as well. And of course, engaging the team makes a big difference because the whole oncology team can help to manage situations that are particularly challenging like that. And just as we close, I wanted to ask one last question of you, Dr. Brenner, that suffering, grief, and burnout, you've really made the point that these are not problems to fix but dimensions that we want to attend to and acknowledge as part of our lives, the dying process is part of all of our lives. It's just dealing with this in the unexpected and the, I think, unpredictability of life, you know, that people take on a lot of guilt and all sorts of things about, all sorts of emotions. And the question is now, people have listened to this podcast, what can they take back to their oncology teams to build a culture that supports clinicians and their team at large to engage with these realities in a meaningful and sustainable way? I really feel like if we could build the whole team approach where we're supporting each other and supporting the patients together, that that will help this process immeasurably. Dr. Keri Brenner: Yes, and I'm thinking about Dr. Sławkowski-Rode's observation about the combat analogy, and it made me recognize this distinction between suppression and repression. Repression is this unconscious process, and this is what we're taught to do in medical training all the time, to just involuntarily shove that tragedy under the rug, just forget about it and see the next patient and move on. And we know that if we keep unconsciously shoving things under the rug, that it will lead to burnout and lack of sustainability for our clinical teams. Suppression is a more conscious process. That deliberate effort to say, “This was a tragedy that I bore witness to. I know I need to put that in a box on the shelf for now because I have 10 other patients I have to see.” And yet, do I work in a culture where I can take that off the shelf during particular moments and process it with my interdisciplinary team, phone a friend, talk to a trusted colleague, have some trusted case supervision around it, or process rounds around it, talk to my social worker? And I think the more that we model this type of self-reflective capacity as attendings, folks who have been in the field for decades, the more we create that ethos and culture that is sustainable because clinician self-reflection is never a weakness, rather it's a silent strength. Clinician self-reflection is this portal for wisdom, connectedness, sustainability, and ultimately transformative growth within ourselves. Dr. Hope Rugo: That's such a great point, and I think this whole discussion has been so helpful for me and I hope for our audience that we really can take these points and bring them to our practice. I think, “Wow, this is such a great conversation. I'd like to have the team as a whole listen to this as ways to sort of strategize talking about the process, our patients, and being supportive as a team, understanding how we manage spirituality when it connects and when it doesn't.” All of these points, they're bringing in how we process these issues and the whole idea of suppressing versus sort of deciding that it never happened at all is, I think, very important because that's just a tool for managing our daily lives, our busy clinics, and everything we manage. Dr. Keri Brenner: And Dr. Rugo, it's reminding me at Stanford, you know, we have this weekly practice that's just a ritual where every Friday morning for 30 minutes, our social worker leads a process rounds with us as a team, where we talk about how the work that we're doing clinically is affecting us in our lives in ways that have joy and greater meaning and connectedness and other ways that might be depleting. And that kind of authentic vulnerability with one another allows us to show up more authentically for our patients. So those rituals, that small 30 minutes once a week, goes a long way. And it reminds me that sometimes slowing things down with those rituals can really get us to more meaningful, transformative places ultimately. Dr. Hope Rugo: It's a great idea, and I think, you know, making time for that in everybody's busy days where they just don't have any time anymore is important. And you don't have to do it weekly, you could even do something monthly. I think there's a lot of options, and that's a great suggestion. I want to thank you both for taking your time out for this enriching and incredibly helpful conversation. Our listeners will find a link to the Ed Book article we discussed today, which is excellent, in the transcript of this episode. I want to thank you again, Dr. Brenner and Dr. Sławkowski-Rode, for your time and for your excellent thoughts and advice and direction. Dr. Mikołaj Sławkowski-Rode: Thank you very much, Dr. Rugo. Dr. Keri Brenner: Thank you. Dr. Hope Rugo: And thanks to our listeners for joining us today. Please join us again next month on By the Book for more insightful views on topics you'll be hearing at the education sessions from ASCO meetings and our deep dives on new approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Hope Rugo @hope.rugo Dr. Keri Brenner @keri_brenner Dr. Mikolaj Slawkowski-Rode @MikolajRode Follow ASCO on social media:      @ASCO on X (formerly Twitter)      ASCO on Bluesky     ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Hope Rugo: Honoraria: Mylan/Viatris, Chugai Pharma Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx Dr. Keri Brenner: No relationships to disclose Dr. Mikolaj Slawkowski-Rode: No relationships to disclose    

Alles auf Aktien
Anlegen wie ein Staatsfonds und Aktienperlen von der Adria

Alles auf Aktien

Play Episode Listen Later Jul 11, 2025 22:27


In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über einen weiteren Bitcoin-Rekord, abhebende Airline-Aktien und eine Verstärkung des AAA-Teams. Außerdem geht es um United Airlines, Delta Airlines, Expedia Group, Nvidia, Levi Strauss, MP Materials, Ramaco Resources, Vertiv Holdings, Hermès International, Microsoft, Apple, Shelly Group (WKN: A2DGX9), Krka (WKN: 903246), Merck & Co., Pfizer, Nova Ljubljanska Banka (WKN: A2N73H), Petrol (WKN: 903244), Zavarovalnica Triglav (WKN: A0D9FA), Luka Koper (WKN: 923271), Telekom Slovenije (WKN: 915855), Expat Slovenia SBI TOP ETF (WKN A2JB7F), Almonty Industries. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Alles auf Aktien
Aktien für den Capex-Superzyklus und die nächste Billionen-Wette

Alles auf Aktien

Play Episode Listen Later Jul 10, 2025 21:13


In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über den neuen Drohnen-Liebling, einen Bitcoin-Rekord und die Rückkehr des Wasserstoff-Hypes. Außerdem geht es um Volatus Aerospace, WK Kellog, EssilorLuxottica, Meta Platforms, Plug Power, Bloom Energy, Ballard Power, L&G Hydrogen Economy ETF (WKN: A2QMAL), Hershey, Nvidia, Apple, Microsoft, Standard Oil/ExxonMobil, General Electric, NTT, Intel, Texas Instruments, Micron Technology, Eli Lilly, Merck, Air Products, Freeport-McMoran, Keysight, Hess, Williams, EQT, Amundi MDax ETF (WKN: LYX0R1), RWE, National Grid, Rio Tinto, Antofagasta, Infineon, ASML, SAP, Leonardo, Astrazeneca, Merck, Novo Nordisk, Almonty Industries. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News
“Drohnen-Highflyer Kratos” - NVIDIA knackt 4.000 Milliarden & Ether = Stablecoin-Profi

OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News

Play Episode Listen Later Jul 10, 2025 13:45


Unser Partner Scalable Capital ist der einzige Broker, den du brauchst. Inklusive Trading-Flatrate, Zinsen und Portfolio-Analysen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. NVIDIA ist wertvollste Firma ever. DAX hat schon wieder Rekord. EssilorLuxottica hat Meta und Commerzbank hat Unicredit als Aktionär. Merck kauft Verona. Bei WPP kauft fast niemand. Starbucks verkauft China. Wer ist nächster Tim Cook? US-Rüstungsaktien laufen dieses Jahr viel schlechter als die europäischen. Eine Ausnahme: Kratos (WKN: A0YAND). Alle wollen Stablecoins. Aber Circle ist sehr teuer. Was jetzt? Eine Wette: Ethereum. Auf der Blockchain laufen die Coins nämlich zu großen Teilen. Was war sonst los in der Kryptowelt? Tether hat Gold, Robinhood ist ein Macher und Figma hat Bitcoin-ETF. Diesen Podcast vom 10.07.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Pharma and BioTech Daily
Pharma and Biotech Daily: Merck's Acquisition, Supreme Court Ruling, and Trump's Tariff Threats

Pharma and BioTech Daily

Play Episode Listen Later Jul 10, 2025 1:04


Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Merck recently made a significant move in the pharmaceutical industry by acquiring Verona for $10 billion, gaining access to the commercial COPD drug Ohtuvayre. This acquisition is viewed as a strategic decision to offset potential revenue loss when the patent for Keytruda expires. In other news, the Supreme Court has suspended an injunction preventing RFK Jr.'s HHS cuts. AstraZeneca also finalized a deal with JCR worth up to $825 million for gene therapy AAVs. Additionally, Trump has threatened 200% pharma tariffs, but has provided a one-year grace period for implementation. Drug developers are being advised to digitize their outsourcing path for optimal success in the industry. Furthermore, Novo Nordisk has terminated a deal with Hims & Hers, while Lilly has received an FDA label update for an Alzheimer's drug. Various developments in the longevity biotech space have also been highlighted. Stay tuned for more updates in the pharmaceutical industry.

MONEY FM 89.3 - Your Money With Michelle Martin
Market View: Temasek's Boom, Copper's Charge & Netflix's Anime Ambitions

MONEY FM 89.3 - Your Money With Michelle Martin

Play Episode Listen Later Jul 10, 2025 25:15


A record-breaking run for Temasek, copper prices soar on Trump’s tariffs, and Netflix bets big on anime. What does Temasek’s strategy tell us about smart investing? Will copper’s surge reshape global supply chains? And is NTT DC REIT Singapore’s next hot listing? Michelle Martin and Ryan Huang break it all down. Companies featured include Temasek, DBS, SingTel, Freeport-McMoRan, Southern Copper, NTT, GIC, BlackRock, Fidelity, Nvidia, Meta, Merck, IHH Healthcare, SGX, UOL, and Netflix.See omnystudio.com/listener for privacy information.

Squawk on the Street
Nvidia Makes History As the First $4 Trillion Market Cap Company 7/9/25

Squawk on the Street

Play Episode Listen Later Jul 9, 2025 42:47


Carl Quintanilla and Jim Cramer covered all of the bases on a historic day for Nvidia: The chipmaker became the first company to achieve a $4 trillion valuation. Hear what Jim had to say about what's ahead for the stock. Also in focus: Apple's Jeff Williams to step down as COO, copper tariffs and what they could mean for Tesla, UnitedHealth and the DOJ, Merck's $10 billion deal to acquire Verona Pharma, President Trump's 200% pharma tariff threat. Squawk on the Street Disclaimer

FactSet U.S. Daily Market Preview
Financial Market Preview - Wednesday 9-Jul

FactSet U.S. Daily Market Preview

Play Episode Listen Later Jul 9, 2025 4:50


S&P futures are pointing to a flat open today. Asian markets traded mixed today with Japan's Nikkei logging small gains, supported by resilience in manufacturing. The Hang Seng underperformed, as property and tech stocks lagged. European markets are trading higher, with the DAX and CAC leading gains. President Trump announced a 50% tariff on copper, set for late July or early August implementation, and proposed a 200% tariff on pharmaceuticals with a longer timeline. He ruled out extending the August 1 deadline, emphasizing his tough stance on trade while accusing BRICS nations of undermining the U.S. dollar and threatening an additional 10% tariff. Companies Mentioned: Apple, Starbucks, Merck, Verona Pharma, AES Corp

NewsWare‘s Trade Talk
NewsWare's Trade Talk: Wednesday, June 9

NewsWare‘s Trade Talk

Play Episode Listen Later Jul 9, 2025 17:42


S&P Futures are positive this morning as the market are anticipating announcement on trade deals. Treasury Secretary Scott Bessent and the Director of the White House National Economic Council Kevin Hassett are being discussed as the top candidates to succeed Jerome Powell as the next Fed Chair. Key economic event today will be the Fed's Meeting Minutes from last months fed meeting. Merck announced a deal to takeover VRNA. Boeing is higher on upbeat news related to plane deliveries. On the earning front, AZZ to release after the close today, tomorrow morning, SMPL, CAG & DAL are scheduled to release.    

TD Ameritrade Network
Stock Market Today: NVDA $4T Market Cap, MSFT Upgrade, MRK & VRNA Merger

TD Ameritrade Network

Play Episode Listen Later Jul 9, 2025 2:00


Boosted tariffs on select countries didn't stop markets from rallying, which led the NDX to hit another new all-time high. Nvidia (NVDA) also reached a new milestone: $4 trillion in market cap, the first company to ever reach the number. Microsoft (MSFT) climbed to a new high off an upgrade from Oppenheimer. Merck (MRK) and Verona Pharma (VRNA) rallied after Merck shared plans to buy Verona for $10 billion. Marley Kayden takes investors through the trading session's top stories.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-...Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-...Watch on Sling - https://watch.sling.com/1/asset/19192...Watch on Vizio - https://www.vizio.com/en/watchfreeplu...Watch on DistroTV - https://www.distro.tv/live/schwab-net...Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

WALL STREET COLADA
Wall Street Sube con Cautela, Super Micro Expande en Europa y Merck Compra Verona por $10B

WALL STREET COLADA

Play Episode Listen Later Jul 9, 2025 4:47


Notas del Show: En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street se estabiliza tras presión arancelaria: Futuros moderadamente al alza tras caídas por anuncios de tarifas del 25–40 % a 14 países y hasta 200 % a fármacos. Hoy se esperan las minutas del FOMC. Ayer: $SPX -0.07 %, $US100 plano, $INDU -0.4 %. • Super Micro apuesta por Europa y Asia: $SMCI ampliará su planta en Países Bajos y evalúa nuevas fábricas en la región para enfrentar demanda de IA. También sumará capacidad en Malasia y Taiwán. Su CEO destacó que, pese a retrasos por GPUs Blackwell de $NVDA, la demanda se mantiene fuerte. • Merck compra Verona Pharma por $10B: $MRK adquirirá $VRNA por 107 USD/ADR (+23 % de prima). Verona comercializa Ohtuvayre, inhalador aprobado por la FDA con potencial en varias enfermedades respiratorias. El cierre se espera para Q4 2025. $VRNA +20 % premarket. • Starbucks atrae fondos en China: $SBUX recibió interés de ~30 fondos para invertir en su filial china, valorada entre $5B–$10B. Mantendría 30 % de participación. Goldman Sachs asesora la operación. China representa ~8 % de sus ingresos globales. • Jeff Bezos vende más acciones de Amazon: $AMZN | Bezos vendió 3 millones de acciones por $0.666B en julio, parte de un plan para desprenderse de hasta 25 millones de títulos (hasta $4.75B) antes de mayo 2026. Sigue siendo el mayor accionista con 900M de acciones (~$200B). Una jornada con foco en adquisiciones, expansión global y nuevos episodios del reordenamiento fiscal y comercial. ¡No te lo pierdas!

Careers in Discovery
Tim Sparey, Tay Therapeutics

Careers in Discovery

Play Episode Listen Later Jul 9, 2025 41:55


This week on Careers in Discovery, we're joined by Tim Sparey, Executive Chair at Tay Therapeutics and Non-Executive Chair at Concr. Tim shares his journey from early days as a medicinal chemist at Merck to a career spanning business development, CEO roles, and now chairing multiple early-stage Biotech companies. He talks about the shift from operator to portfolio leader, how he evaluates new opportunities, and why capital efficiency is a critical part of Biotech success - especially in the current market. We also dive into Tay's approach to doing more with less, how Concr is applying AI to reshape precision oncology, and what Tim looks for in founding teams. Along the way, he reflects on the value of learning from setbacks, building trust with investors, and why simplicity, storytelling, and timing make all the difference.

IDEA Collider
Bold Science, Bigger Bets: Mathai Mammen on Visionary R&D and Transforming Biopharma

IDEA Collider

Play Episode Listen Later Jul 9, 2025 50:20


In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies. 00:00 Introduction and Guest Background00:56 Founding Thebans and Career Highlights01:43 Leadership at Merck and J&J02:18 Innovative Approaches at Parabilis Medicines04:09 Defining and Tackling Undruggable Targets09:27 Multivalent Drug Design and Bispecifics13:53 AI and Data Science in Drug Development19:28 Building and Leading World-Class Teams25:41 The Importance of Holding Conviction as an Entrepreneur26:25 Learning from Setbacks in the Biotech Industry30:10 Challenges and Innovations in Drug Development32:28 Navigating the Ups and Downs of the Biotech Industry36:02 The Mission and Future of Parabilis40:35 Personal Reflections and Advice for Entrepreneurs46:46 Book Recommendations and Closing Thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Mathai Mammen;LinkedIn: https://www.linkedin.com/in/mathai-mammen/Website: https://parabilismed.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Mercado Abierto
El análisis del día en Wall Street

Mercado Abierto

Play Episode Listen Later Jul 9, 2025 9:17


Repaso a los protagonistas del día, como Merck, AES Corporation, Apple o UnitedHealth con Celso Otero, de Renta 4.

The Skeptic Metaphysicians - Metaphysics 101
Jimi Merck's Sacred Symbols and Psychic Healing: Spirit Fest USA Special

The Skeptic Metaphysicians - Metaphysics 101

Play Episode Listen Later Jul 6, 2025 10:55


Celebrity psychic healer. Master jewelry alchemist. Light warrior mentor.In this mesmerizing episode recorded live from Spirit Fest USA - Dulles, we sit down with the multidimensional force that is Jimi Merck—an internationally recognized psychic healer, medical intuitive, clairvoyant, hypnotist, and visionary jewelry designer. From surviving a near-death experience as a child to designing sacred, energetically encoded jewelry seen on celebrities and spiritual leaders alike, Jimi shares his remarkable journey of awakening and purpose. His creations are more than jewelry—they're three-dimensional prayers, carved in sacred ratios, cast in palladium-infused silver, and embedded with universal healing stones to awaken our soul's memory. But that's just the beginning…In This Episode, You'll Discover:How ancient sacred symbology revealed itself to Jimi at age 16 and became a healing language of creation.Why his jewelry is more than art—it's a functional energy healing tool that helps the body detox and recalibrate.The story of his traumatic brain injury and resurrection, which activated his lifelong psychic abilities.His process for helping clients heal inherited trauma, unlock soul gifts, and remember who they truly are.What it means to be a “light warrior” and how Jimi trains others to step into their spiritual power.Why true healing begins with one essential act: radical self-love.About Jimi Merck Jimi is the founder of Shine Your Light Wellness, a platform offering remote psychic healing, intuitive guidance, and transformational coaching. Over the last 25 years, he has:Sold over 110,000 pieces of healing jewelry worldwideWorked with 12,000+ clients including athletes, celebrities, and politiciansTaught over a million students through workshops and live eventsMastered 30 healing modalities and studied 12 global shamanic traditionsHe's known for helping clients unlock their soul's potential in just one session—and for crafting sacred tools that awaken your spiritual DNA.Connect with Jimi Merck

Vietnam Innovators
The Pharmaceutical Industry and New Development Prospects for Vietnam's Economy - Katharina Geppert, MSD Vietnam - S6#57

Vietnam Innovators

Play Episode Listen Later Jul 3, 2025 28:29


Vietnam is emerging as one of the fastest-growing pharmaceutical markets in Southeast Asia. Rising healthcare demands, coupled with ongoing policy reforms, are creating exciting new opportunities. However, these developments also present significant challenges that businesses in the industry must navigate. So, what does it take to unlock the full potential of this dynamic and fast-evolving market?Our guest on this week's English edition of Vietnam Innovators is Ms. Katharina Geppert, Managing Director, MSD Vietnam, who has spent over four years living and working in Vietnam. Drawing from her leadership experience across multiple major markets, Ms. Geppert offers valuable insights into MSD's growth strategies, emerging trends in the pharmaceutical industry, and the collaborative opportunities between businesses and policymakers to build a more sustainable healthcare ecosystem for Vietnam.Thank you MSD Vietnam for accompanying Vietnam Innovators. MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, is one of the premier research-intensive biopharmaceutical companies in the world. With more than 130 years of experience, MSD is at the forefront of research, delivering innovative health solutions that advance the prevention and treatment of diseases in both people and animals. The company fosters a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, please visit www.msd.com and http://www.msd-vietnam.com; and connect with the MSD team on Twitter, LinkedIn, and YouTube...—Listen to this episode on ⁠YouTube⁠And explore many amazing articles about the pioneers at: ⁠⁠https://vietcetera.com/vn/bo-suu-tap/vietnam-innovator⁠Feel free to leave any questions or invitations for business cooperation at ⁠hello@⁠⁠vni-digest.com

The Robyn Engelson Podcast
Ex-convict to Transformational Leader

The Robyn Engelson Podcast

Play Episode Listen Later Jul 3, 2025 36:37


The Robyn Engelson Podcast Ever wish you had a life mentor with over decades of experience whispering million dollar tips in your ear? That's exactly what you will get each week when you tune into The Robyn Engelson Podcast. I'm your host, a sought after burnout recovery coach for high-achieving women and help you heal from burnout and survival mode, so you can reclaim your energy, joy, and rediscover your voice. Each week, I bring you inspiring guests, insights, and tools to empower you to be energized, compress time, and start living instead of existing.   Episode Title: How Do You Rebuild After Losing Everything? Host: Robyn Engelson Guest: Rashmi Airan Episode Summary:  In this episode, we sit down with Rashmi Airan, former attorney, Wall Street investment banker, and now a speaker, leadership guide, and fierce advocate for redefining success. Rashmi's story is not about perfection. It's about truth, ownership, and rising with purpose. After being indicted for bank fraud and serving six months in federal prison, Rashmi faced the loss of everything she thought defined her: her career, her reputation, her status. But in the ashes, she discovered something far more powerful, her real self. Now, Rashmi uses her story to help others rise. Through her RISE Process: Reframe, Identify, Surrender, Evolve. She invites us to let go of shame, redefine our worth, and lead with authenticity. This conversation is for anyone who has ever felt like failure was the end. Rashmi is here to remind you: it might just be the beginning.    You'll learn: How did prison become the start of personal transformation? Why is letting go of ego the key to real growth? What the RISE Process looks like — and how to use it? How did gratitude journaling change Rashmi's life? Why do most women leaders set boundaries without guilt? What happens when you embrace vulnerability as strength?   Memorable Quotes: “I got eulogized before I died. And I realized people loved me… not for my success, but for me.” – Rashmi “Not doing something is still doing something wrong.” – Rashmi “It's not about the fall. It's about who you become when you rise.” – Robyn   Resources & Mentions: https://rashmiairan.com   Actionable Steps for Listeners: 1. Reflect on a Moment You Reframed Was there a time you turned pain into purpose? Write it down. Let it guide you. 2. Start a Gratitude Journal One line a day. Especially on hard days. It changes everything. 3. Identify Your Support Circle Who helps you stay grounded? Reach out. Tell them they matter. 4. Share Rashmi's Story Send this episode to someone who feels like they're in a low moment. Remind them they're not alone.   Final Thought: Your worth isn't defined by what you achieve, but by how you show up, even when everything falls apart. Like Rashmi says: “You can lose everything, and still find your purpose.”    What listeners have to say: “I cried when Rashmi said she thought no one would pick up her call. This episode is a must-listen.” – David M., entrepreneur “This is the most honest conversation I've heard on leadership and failure.” – Alisha T., executive coach “Gratitude journaling in prison? I'm rethinking everything I complain about.” – Marissa G., C-suite mom   These stories remind us:  Failure isn't the end. It's an invitation to evolve.  Success means nothing if you lose yourself in the process.  True connection comes from authenticity, not achievement.   Now it's your turn: Which part of Rashmi's journey resonated most with you? Have you ever felt like your worth was tied to your achievements? We'd love to hear. DM us, tag us, or share your story. You never know who it might inspire.   Loved this episode? If you found value in this conversation, don't forget to leave a review! Scroll to the bottom, tap to rate with five stars, and select “Write a Review.” Your feedback helps us create content that supports your journey to thriving, not just surviving.   Connect with Rashmi Airan: Facebook Youtube Instagram Linkedin   About  Rashmi Airan: Rashmi Airan is a force of nature. A keynote speaker, consultant, and unapologetic truth-teller, she shakes up rooms with her raw, riveting story. One that challenges everything you think you know about leadership, ethics, and the hidden traps of ambition. She doesn't just speak about resilience; she lives it, proving that even the most crushing failures can be transformed into a catalyst for growth, authenticity, and unshakable courage. As a first-generation Indian American, Rashmi was raised to chase excellence. She did just that. Graduating with honors from Columbia Law School, thriving in corporate America, and building her own law practice. But success has a dark side. During the housing boom, she made a decision that, at the time, seemed small, but had devastating consequences. A single ethical blind spot, fueled by the pressure to provide for her children, led to a federal prison sentence for bank fraud. Prison shattered everything she thought she knew about herself. And then? She rebuilt: stronger, bolder, and more awake than ever. Through six months behind bars, Rashmi stripped away the layers of ego, guilt, and fear that had defined her. She emerged with a powerful message: our worst mistakes don't define us, our responses to them does. Now a "recovering government, corporate, and real estate lawyer," Rashmi is a globally recognized speaker who fearlessly tackles the complexities of human behavior, decision-making, and ethical leadership. With 30+ years in business, law, and finance, she has a front-row seat to the pressures that push good people into bad decisions, and she's on a mission to wake up individuals and organizations before they fall into the same traps. Her insights are backed by cutting-edge research in behavioral psychology, ethics, and leadership, and she's partnered with global powerhouses like Coca-Cola, Cardinal Health, Merck, Comcast, Sotheby's, and Hershey's. Deloitte has recognized her transformational impact, and her story has been featured on ABC, PBS, The Washington Post, and The Wall Street Journal. Rashmi doesn't do surface-level inspiration. She sparks deep, uncomfortable, necessary conversations. She challenges Fortune 100 leaders, financial firms, legal teams, and women's groups to confront their blind spots, own their decisions, and rise through their struggles with integrity and courage. Beyond the stage, she's an avid hiker, globe-trotter, and proud mother of two. She serves on the Board of Directors for the Overtown Youth Center/Alonzo Mourning Foundation and is an Ambassador for The Key Clubhouse. Her message is simple but urgent: Life will break you. Your choices will define you. And no matter how hard you fall: you can RISE.   Connect with Robyn: Bring Robyn to Your Stage Get Robyn's #1 best selling book, Exhausted To Energized - 90 Days To Your Best Self Get Robyn's Free Back To You: From Chaos To Clarity Video Sign up for Robyn's Unapologetic Personal Letter   View Robyn's Website Follow Robyn on LinkedIn Watch Robyn on Instagram Robyn's Facebook      

Adpodcast
Ian Orekondy - Director of Media, Analytics & Innovation - Method1

Adpodcast

Play Episode Listen Later Jul 3, 2025 18:21


Ian Orekondy is the Director of Media, Analytics & Innovation at Method1, where he applies data-driven strategies and behavioral science to optimize media planning and brand impact for clients like PepsiCo, Gap, and Merck . Joining Method1 in early 2024, Ian has nearly two decades of experience across media, analytics, product, and ad-tech leadership roles Before Method1, Ian founded PranifyRx, an AI-powered ad data platform focused on pharmaceutical marketing, and held senior product and leadership positions at AdComplyRx, Good Apple, United Business Media, and Rosetta . He holds a B.S. in Business Administration from SUNY Buffalo and earned an altMBA certificate from Seth Godin signalhire.com.Ian's cross-functional expertise in connecting technology, analytics, and creative strategy makes him a key driver of innovative, measurable campaigns in a privacy-first world.

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1

Smart Biotech Scientist | Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Play Episode Listen Later Jul 1, 2025 13:30


Ever feel like you're drowning in an ocean of constantly shifting regulatory guidelines? The world of biotech is a whirlwind of evolving standards, making compliance not just a headache, but sometimes the stumbling block between life-changing therapies and the patients who need them. But what if artificial intelligence could turn regulatory chaos into your biggest competitive advantage?In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck KGaA's Global Analytical Development. Abhijeet shares how he's pioneering the use of generative AI, not as a hype machine, but as a practical, transformative tool for regulatory compliance in biotech. With over a decade navigating analytics, digitalization, and collaborative tech adoption at a major pharma leader, Abhijeet knows what it takes to connect industry stakeholders, harness new technologies, and turn business operations into streamlined, value-generating systems.Here are three reasons you won't want to miss this episode:Generative AI as a Compliance Powerhouse: Discover how AI is being harnessed to analyze, extract, and compare complex regulatory requirements across different countries, cutting through ambiguous language and shifting specifications - so you don't have to.Reducing Regulatory Bottlenecks: The days of manually reconciling guideline documents and updating baselines with every regulatory change are numbered. Learn how generative AI accelerates multi-guideline comparison, saving teams countless hours and reducing the risk of costly errors and delays.A Blueprint for Digital Transformation: Abhijeet reveals how Merck is moving from proof-of-concept to operational reality, building collaborative teams that bridge IT, analytics, regulatory, and quality to bring valuable digital tools into daily practice.Curious if your team could automate away regulatory headaches? Listen in and get inspired to tackle your toughest compliance challenges - before your competitors do.Connect with Abhijeet Satwekar:LinkedIn: https://www.linkedin.com/in/abhijeetsatwekarNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotechSupport the show

TriloTalk
Episode 35: Introducing the AMWA Apprentice Program Framework – A step-by-step guide to training medical writers

TriloTalk

Play Episode Listen Later Jun 30, 2025 32:15


The demand for experienced medical writers is outpacing the availability of experienced writers. In TriloTalk episode 35, Julia Forjanic Klapproth, Senior Partner at Trilogy, and Kim Jochman, Senior Director of Medical Writing at Merck, raise awareness of two new essential AMWA resources: the apprentice program framework and the job leveling framework. As members of the workstreams who developed these, Julia and Kim bring insights and the rationale from behind the scenes. Tune in and learn about these important initiatives for the medical writing community.  

This Week in Virology
TWiV 1230: Clinical update with Dr. Daniel Griffin

This Week in Virology

Play Episode Listen Later Jun 28, 2025 49:13


In his weekly clinical update, Dr. Griffin with Vincent Racaniello are alarmed at how RFK is breaking his promise of not altering vaccine policies, and nonexistent data and studies are used by members of the ACIP to make changes to immunization practices in the absence of a CDC director, justification for not honoring the US commitment to GAVI and global public policies including support of routine childhood immunizations, placing millions of children at risk for the return of vaccine preventable diseases including polio outbreaks in Pappa New Guinea and increased circulation of wildtype type 1 poliovirus, before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, approval of Merck's anti-RSV mRNA monoclonal antibody, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, immunization recommendations for COVID-19 vaccines, where to find PEMGARDA, changes in COVID mRNA vaccine labeling and reframing of the science around the vaccine, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, and contacting your federal government representative to stop the assault on science and biomedical research Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Jake Scott (Stanford University) Vaccine Randomized control trials (Bradspellberg.com) Vaccine RCT spreadsheet aims to show the data, dispel myths about vaccines  (CIDRAP) Vaccines-rcts (Bradspellberg.com) CDC's upcoming vaccine advisory meeting set up to sow distrust in vaccines (CIDRAP) Next ACIP meeting (CDC: ACIP) June meeting: MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) (CDC: ACIP agenda) Robert F Berman, PhD (UC Davis Health: Department of Neurological Surgery) Transparency = nonexistent data: CDC advisers appears to cite nonexistent study to support claims about risk of vaccine preservative (CNN) A C.D.C. Committee Just Voted Against Flu Shots With This Preservative. Is It Safe? (NY Times) CDC vaccine advisory committee to review long-approved immunizations (STAT News) Newly appointed CDC vaccine advisory committee holds first meeting, stirs more controversy (CIDRAP) FDA approves clesrovimab to protect infants during first RSV season (Contemporary Pediatrics) ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination (Contemporary Pediatrics) Susan Monarez (Wikipedia) Robert F Kennedy Jr (Wikipedia) Centers for Disease Control and Prevention (Wikipedia) Who is in charge at the CDC (CDC: About CDC) Do children REALLY need to be vaccinated? (Wall Street Journal) U.S. Adults' Views on Routine Childhood Vaccination (Harvard Opinion Research Program) RFK Jr. declares US withdrawal from GAVI (YouTube) Kennedy Withdraws U.S. Funding Pledge to International Vaccine Agency (NY Times) Millions of children at risk as global vaccine rates fall (Guardian) Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030 (LANCET) Polio this week: 47 WPV1 positive environmental samples this week! (GPEI) H5 bird flu: current situation (CDC: Avian Influenza) Cambodia logs fifth death from H5N1 avian flu as USDA weighs poultry vaccination (CIDRAP) Cambodia reports 6th H5N1 bird flu case this year(BNO News) USDA develops potential plan to vaccinate poultry for bird flu (Reuters) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Weekly measles and rubella monitoring (Government of Canada) Measles vaccine recommendations from NYP (jpg) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Novel Drug Approvals for 2025 (FDA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (biRxiV) Episode 184: Fool's Gold: Reframing the Science…..reframing? (Apple Podcasts: Osterholm Update) Children with Post COVID-19 Multisystem Inflammatory Syndrome Display Unique Pathophysiological Metabolic Phenotypes (Journal of Proteome Research) FDA COVID mRNA vaccine labeling update (FDA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Stellate Ganglion Block for the Treatment of COVID-19−Induced Parosmia (JAMA Otolaryngology-Head& Neck Surgery) Reaching out to US house representative Letters read on TWiV 1230 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Working Ranch Radio Show
Ep 218: What Actually Pays A NET Premium on Your Calves?

Working Ranch Radio Show

Play Episode Listen Later Jun 28, 2025 54:00


Today we look at some very basic management practices that data shows will increase the value of your calves when you go to market them.  The values has been derived from data through a partnership between Superior Livestock, Kansas State University, and Merck Animal Health.  So today Dr. Chris Thomsen with Merck joins us as he walks us through the data.  From breeding management to calfhood management, that also includes looking at the ROI on Precondition... what about Weaning? And what about the four things that DOESN'T affect the value of your calves?  Tune in to find out what those four things are and What Actually Pays a Net Premium on Your Calves! #workingranchmagazine #ranchlife #ranching #dayweather #weather #agweather #beef #cows #livestock #cattle #lowstress #k-line #RioMax #ManSaver #Gelbvieh #TankToad #Marketing #Weaning #Preconditioning #breeding

ASCO Daily News
Immunotherapy at ASCO25: Drug Development, Melanoma Treatment, and More

ASCO Daily News

Play Episode Listen Later Jun 27, 2025 27:01


Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Squawk on the Street
The AI Boom: Nvidia's Record Run, Micron CEO Exclusive 6/26/25

Squawk on the Street

Play Episode Listen Later Jun 26, 2025 45:38


David Faber and Jim Cramer discussed he AI boom helping to boost the tech rally. Nvidia hitting a new all-time and surpassing Microsoft to become the world's most valuable company. Micron CEO Sanjay Mehrotra joined the program exclusively to discuss the role AI played in the chipmaker's better-than-expected earnings and upbeat guidance. Also in focus: Microsoft and Meta go after OpenAl for different reasons, Tesla vs. Waymo on robotaxis, McCormick's spicy earnings, Q1 GDP shrinks more than expected, RFK Jr.'s vaccine panel backs Merck's RSV shot for infants, Cramer's message on skyrocketing stocks and the "FOMO" trade. Squawk on the Street Disclaimer

Gut Talk
Dedication, Innovation, Inspiration with Miguel Regueiro, MD

Gut Talk

Play Episode Listen Later Jun 25, 2025 45:20


In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more. •    Intro :58 •    The interview/about Regueiro 1:03 •    Tell us about your family and where you grew up. 1:24 •    How did you get interested in medicine? 2:16 •    Who were your early influences?  4:18 •    What is the medical home? 5:57 •    How did you develop the idea to apply the medical home model to IBD? 7:45 •    Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57 •    Why hasn't this model become standard of care for patients with complex IBD? 14:13 •    What has worked, and what hasn't worked when it comes to adopting an integrative care medical home model? 18:15 •    Are there themes patients share as to why they wouldn't want to be enrolled in a medical home? 21:28 •    What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09 •    What have you learned in this position at Cleveland Clinic? 25:23 •    Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34 •    How would you recommend that people prepare for having a position like this? 27:34 •    Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02 •    With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06 •    What are the challenges that you still see in the ways we are using telehealth? 39:05 •    What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26 •    Thank you, Miguel 42:55 •    Thanks for listening 45:11 Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X. Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.

The Highwire with Del Bigtree
FDA APPROVES MERCK'S RSV SHOT DESPITE ALARMING INFANT TRIAL DATA

The Highwire with Del Bigtree

Play Episode Listen Later Jun 24, 2025 19:49


Del and Jefferey dive into the troubling numbers behind Merck's new RSV shot for infants, recently greenlit by the FDA. Trial data revealed higher rates of deaths and severe respiratory illness in vaccinated babies, yet the FDA overlooked this concerning trial data.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.